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     Persistent pulmonary hypertension of the newborn (PPHN) is a very serious disease 
affecting nearly 5 in 1000 newborns each year.  The development of PPHN has been 
linked to a decrease in the activity and expression of endothelial nitric oxide synthase 
(eNOS).  Thus, it is critical to understand the mechanisms by which eNOS is regulated to 
identify new pathways and novel therapies for PPHN.  eNOS is dynamically regulated at 
the transcriptional, post-transcriptional, post-translational, and developmental levels, 
however mechanisms of this regulation are unresolved.  Our data indicates that increases 
in eNOS expression and activity correlate with increased cellular levels of labile zinc 
(Zn).  In addition, our analysis of the eNOS promoter indicated the presence of a putative 
heavy metal response element (HRE) in the 5’-flanking sequence.  We hypothesized that 
nitric oxide (NO) may be regulating eNOS expression and activity indirectly through its 
ability to regulate cellular levels of free Zn.  Further, we hypothesized that Zn exerts an 
effect on eNOS at the transcriptional and post-translational levels.  Our results suggested 
that both NO and hydrogen peroxide (H2O2) activate eNOS in a Zn-dependent manner by 
liberating cellular stores of Zn and activating the heavy metal-responsive transcription 
factor 1, MTF-1, which then would bind to the eNOS 5’-regulatory MRE.  We found that 
basal zinc levels in endothelial cells (ECs) helped maintain eNOS promoter activity and 
total protein levels, but did not affect eNOS dimer levels.  However, supplementing ECs 
with exogenous Zn increased eNOS total and dimer protein levels and activity, mostly 
through MTF-1.   At higher, non-toxic doses of Zn, reactive oxygen species (ROS) 
production was much higher.   eNOS was inhibited by high ROS levels through enzyme 
fragmentation.  Lastly, an eNOS enzyme cofactor, tetrahydrobiopterin (BH4), was found 
to help maintain eNOS protein due to its high antioxidant potential.  In conclusion, eNOS 
appears to be regulated by NO and ROS through an increase in intracellular Zn, thus 
activating MTF-1, which binds to the 5’ flanking region of the eNOS promoter. 
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COMMON INTRODUCTION
Persistent Pulmonary Hypertension of the Newborn (PPHN) 
The foramen ovale, which links the two atria of the fetal heart, and the ductus 
arteriosus, which links the main 
pulmonary artery with the 
descending aorta, are both 
important in allowing fetal blood 
to bypass the pulmonary circuit 
and the collapsed non-functional 
fetal lungs.  Prior to birth the open 
foramen ovale and ductus 
arteriosus cause the pulmonary 
vascular resistance (PVR) to be 
high, but at birth with the loss of the placenta PVR rapidly falls.  Since pressure and flow 
are inversely related, this decrease is associated with an 8-10-fold increase in blood flow 
[1-3], allowing the fetal lungs to establish gas exchange. PVR then continues to fall 
gradually during the newborn’s first month [4].  However, in a number of clinical cases 
in the term or near term infant, there is a failure of the pulmonary circulation to undergo 
the normal transition to postnatal life, resulting in persistent pulmonary hypertension of 
the newborn (PPHN).  PPHN is a very serious disease that can be triggered by a number 
of events such as meconium aspiration syndrome, respiratory distress syndrome, 
pneumonia, sepsis, or severe hypoxia [4].  It is thought to be responsible for 
approximately 10% of admissions to neonatal intensive care units and affects nearly 5 in 
Figure 1:  EMCO 
(http://www.gla.ac.uk/surgicalpaediatrics/images/
VA_ECMO_circuit_.jpg) 
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1000 newborns each year [5].  The disorder is associated with significant morbidity and 
mortality [5].
Initially, these hypertensive infants are put on oxygen and if this is not sufficient, 
then they are given inhaled nitric oxide.  Extra corporeal membrane oxygenation 
(ECMO) is considered the most advanced therapy for extreme cases.  Essentially, ECMO 
is a heart lung bypass machine that is connected to the infant via an arterial cannula 
(Figure 1).  Inhaled nitric oxide reduces the  use of ECMO in these PPHN infants [6].  
PPHN can be associated with extensive vascular remodeling.  Figure 2 
demonstrates this remodeling with arterial cross sections from normal and pulmonary 
hypertensive states.  Obvious intima and adventitia hypoplasia is evident as well as 
thickening of the adventitia, media, and intima.  These alterations result in a much 
smaller luminal diameter and therefore, a much lower blood flow.  
Figure 2.  Arterial cross sections from normal and PPHN states.  L labels the lumen of the 
vessels.
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Endothelial Nitric Oxide Synthase (eNOS)
The fetal to newborn transition is dependent on 
the functioning of the enzyme endothelial nitric oxide 
synthase (eNOS).  In fact, the development of PPHN has 
been linked to a decrease in the activity and expression of 
eNOS.  Endothelial NOS expression is largely tissue 
dependent.  eNOS is predominantly expressed in 
endothelial cells (EC), although studies have also 
shown eNOS expression in bronchiolar epithelial 
cells [7, 8].  eNOS helps to maintain vascular 
homeostasis by generating nitric oxide (NO).  This 
NO keeps the vasculature dilated, protects the 
intima of the vessels from platelet aggregation and 
leukocyte adhesion and prevents proliferation of 
vascular smooth muscle. Originally thought to be a constitutively expressed enzyme, 
eNOS is now known to be modulated by a variety of chemical, physical, and 
developmental stimuli [9].  The regulation of this enzyme’s protein expression has been 
demonstrated at the developmental, transcriptional, post-transcriptional and post-
translational levels [10-15].  However, the mechanisms of this regulation are yet to be 
resolved.
a. Developmental Regulation of eNOS 
Basal and agonist-stimulated endothelial production of NO has been demonstrated in 
the fetal, newborn, and adult pulmonary vasculature [16-20].  Immunostaining for eNOS 
Figure 3.  Ovine fetal 
endothelial cells have 5-6 fold 
higher eNOS protein levels 
compared to adult endothelial 
cells.  Fetal and adult 
endothelial cells were grown to 
confluency.  Protein was 
harvested and western blot 
analysis was used to look at 
eNOS protein levels.  All values 
are mean ± SEM (n=4). * 
P<0.05 vs. Fetal. 
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is seen as early as 29% gestation in the fetal lamb lung and physiologic studies of 
intrapulmonary arteries and isolated lung preparations of the sheep reveal maturational 
increases in NO-mediated relaxation during the late fetal and early postnatal period [18, 
19, 21, 22].  For example, in ovine intrapulmonary arteries, basal NO production rises 2-
fold from late gestation to 1 week of life, and another 1.6-fold from 1-to-4 weeks of life 
[19].  Similarly, in the pig, there is an increase in NO-mediated relaxation during the first 
two weeks of life, followed by a 
decrease.  Coinciding with this 
physiologic data, eNOS mRNA and 
protein increase during late gestation 
and perinatal periods and decrease 
post-natally in a rat and sheep 
parenchyma [19, 21, 23-25].   
Pitt and colleagues have carried 
out elegant studies indicating that NO 
donors can induce an increase in 
labile zinc in adult ovine PAECs [26, 
27].  At least part of the mechanism 
for this increase appears to be S-nitrosylation of metallothionein [27-29].  However, it is 
unknown if developmental differences in basal levels of labile zinc exist in endothelial 
cells.  My data indicated that increased cellular levels of labile Zn, measured with the 
zinc fluorophore zinquin, correlate with increases in eNOS expression and activity 
Figure 4.  Ovine fetal endothelial cells have 
2-fold higher free zinc levels compared to 
adult endothelial cells.  Fetal and adult 
endothelial cells were grown to confluence.
Cells were then loaded with zinquin ethyl 
ester and visualized using fluorescent 
microscopy.  All values are mean ± SEM 
(n=4). * P<0.05 vs. Fetal. 
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(Figure 3 & 4).  These studies focused on the potential role played by the NO and zinc in 
regulating eNOS gene expression.
It is worth noting that the other two NOS isoforms, neuronal NOS (nNOS or NOS I) 
and inducible NOS (iNOS or NOS II) are also expressed in the lung and appear to be also 
developmentally regulated and 
differentially distributed in 
pulmonary vessels and airways of 
fetal lungs [20, 23, 25, 30].  
However, we focused our studies 
on eNOS since it is intimately 
involved in the control of blood 
pressure and its protein and activity 
levels are decreased in PPHN.   
a. Transcriptional Regulation 
Indeed, the eNOS promoter contains a plethora of putative cis-elements, including 
Sp-1 and GATA motifs, a sterol regulatory element, estrogen-responsive elements, a 
nuclear factor 1 element, a cAMP-responsive elements, and activator protein (AP-1 and -
2) binding sites [24, 31, 32] that would allow eNOS to be regulated by many different 
signals.  Basal eNOS expression has been shown to be regulated in ECs by a complex 
interaction between two tightly clustered cis-regulatory regions defined as positive 
regulatory domains I (-104/-95 relative to initiation site) and II (-144/-115) [33].
Data from our laboratory indicated that increases in eNOS expression and activity 
correlated with increases in the cellular levels of labile zinc (Zn) (Figures 3 & 4).  In 
Figure 5.  eNOS structure and cofactors. 
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addition, our analysis of the eNOS promoter indicated the presence of a putative heavy 
metal response element (HRE) located at -899/-893 in the 5’-flanking sequence of the 
human eNOS gene. 
b. Post-translational Regulation 
Recent evidence suggests that normal pulmonary vascular reactivity and vascular 
smooth muscle cell proliferation are regulated by a complex interaction of vasoactive 
substances produced by the endothelium [34-36].  Previously published research 
indicates that eNOS is only active as a dimeric enzyme and that the dimer is stabilized by 
the formation of a zinc tetrathiolate cluster, in which two cysteine thiolate ligands are 
contributed by each subunit [37-39].  When active and tightly coupled, eNOS catalyzes 
the oxidation reaction of L-arginine and molecular oxygen to L-citrulline and NO [40].  
Once released from endothelial cells, NO diffuses into vascular smooth muscle cells and 
activates 1 and 1 subunits which catalyzes production of guanosine-3',5'-cyclic 
monophosphate (cGMP) from guanosine-5'-triphosphate.  cGMP induces vascular 
smooth muscle relaxation through activation of a cGMP-dependent protein kinase [41].  
Endothelium-derived NO (and the resulting cGMP) is an important mediator of vascular 
tone and an inhibitor of platelet aggregation and smooth muscle mitogenesis [42, 43].  
However, under certain conditions, NOS may generate reactive oxygen species 
(superoxide and hydrogen peroxide) rather than NO.  This process is referred to as NOS 
uncoupling, meaning that NADPH oxidation and NO synthesis have become uncoupled.  
It is important to note that a series of in vitro biochemical studies demonstrated that 
eNOS is the most tightly coupled of all the NOS isoforms [30, 37-39] and definitive in 
vivo and in vitro evidence that uncoupling of eNOS can occur is missing from the 
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literature.  Thus, the mechanisms of eNOS  uncoupling in ECs are not completely 
understood.  Our data indicated that the addition of exogenous zinc to endothelial cells 
significantly increased NO generation. 
c. Reactive Oxygen Species (ROS) Regulation 
The development of hypertensive states in both the pulmonary and systemic 
circulatory systems is associated with increased vascular reactivity and the disruption of 
these regulatory mechanisms [44-49].  Inhibition of eNOS is one of the hallmarks of 
developing endothelial cell dysfunction [50-53].  The last several years have revealed that 
oxidative inactivation of NO is likely to be important in the development of several 
pathologic conditions including atherosclerosis, hypercholesterolemia, hypertension, and 
diabetes [54].  Studies have shown that in blood vessels, the balance existing between the 
steady state levels of NO and the superoxide anion appears to be disrupted resulting in a 
decrease in the bio-availability of NO [42, 54].  For example, large amounts of nitrogen 
oxides are released from vessels in an oxidatively degraded state in cholesterol-fed 
rabbits [55].  Treating these rabbits with polyethylene-glycosylated superoxide dismutase 
(SOD) dramatically increased endothelium-dependent vascular relaxation, suggesting a 
role for superoxide in oxidative inactivation of NO [56]. Vascular superoxide production 
in cholesterol-fed rabbits appeared to be from xanthine oxidase, because production was 
inhibited by the specific inhibitor oxypurinol [57].  Published results show increased 
levels of xanthine oxidase in the plasma of cholesterol-fed rabbits, and this circulating 
xanthine oxidase binds to heparin-binding sites on the vessel, where it acts to produce 
excess superoxide [57].  Evidence demonstrates that reactive oxygen species also 
diminish NO bioactivity in humans.  For example, infusion of ascorbic acid improves 
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vascular responses to acetylcholine in cigarette smokers [58].  In the endothelium, 
cycloxygenase [59], xanthine oxidase [60], and NADPH oxidase [61] have been 
identified as significant producers of superoxide.  More recent studies have indicated that 
NOS itself may also be a significant producer of superoxide during the development of 
nitrate tolerance [48].  Interestingly, the use of PKC inhibitors was shown to decrease the 
production of superoxide in the tolerant vessels although the mechanism of this effect 
was not clear [48].  NOS may produce superoxide when the bioavailability of 
tetrahydrobiopterin or L-arginine are low [62].  Both superoxide and NO are free radicals 
(i.e., they contain an unpaired electron in their outer orbital). When exposed to each 
other, they undergo a facile radical-radical reaction that proceeds at a rate recently 
estimated to be 7 x 109 mol-1.L.s-1 [63, 64]. This is approximately three times faster than 
the reaction rate for superoxide with either the Mn- or CuZn SOD.  Thus, in a 
compartment in which both NO and SOD exist, there may be a propensity for superoxide 
to preferentially react with NO rather than SOD, depending on the relative concentrations 
of NO and SOD present. 
Every cell type in the vascular wall, including fibroblasts [65], endothelial cells 
[66, 67], and smooth muscle cells [68], has been shown to produce and be regulated by 
ROS.  This oxidant production plays an important role both in the normal functioning of 
the vascular system, as well as the pathogenesis of vascular disease.   
A common property of the many stimuli that increase eNOS expression is the 
ability to increase the production of reaction oxygen intermediates (ROIs).  In small 
amounts, these ROI can be stimulating, however, at high levels, our lab has shown them, 
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specifically hydrogen peroxide (H2O2) and nitric oxide (NO), to induce apoptosis and 
mitochondrial dysfunction in pulmonary aortic ECs [69, 70]. 
H2O2, most commonly produced when superoxide (O2.-) is dismutated by 
superoxide dismutase (SOD), is the most stable and long lasting of the ROS [71].  It has 
been previously shown that H2O2, but not O2.- or hydroxyl radicals (OH.), increase eNOS 
expression by increasing both the rate of transcription of eNOS gene and the stability of 
the eNOS message once it is formed [9].    Previous studies done in a cell-free system 
have indicated that H2O2 releases zinc from metallothionein [72].  By exposing cells to 
certain levels of NO, either through exogenous NO [73, 74] or by upregulation of 
inducible nitric oxide synthase (iNOS) activity [75], other studies have also seen 
increases in intracellular labile zinc (Zn2+) levels.  We have previously demonstrated that 
maintaining zinc homeostasis is important in endothelial cell viability [69, 70]. 
Nitric Oxide and Zinc   
Nitric oxide (NO) is a signaling molecule involved in several physiological 
processes such as vasodilation.  NO can react with metal containing proteins (especially 
hemoproteins) at rates limited only by diffusion.  These proteins may represent a primary 
target for NO.  In fact the cellular effects of NO were initially believed to be due its 
affinity for heme and non-heme iron [76].  However, the number of pathophysiological 
pathways mediated by NO has been expanding to include processes that are independent 
of heme and non-heme iron.  Alternative reaction pathways for NO have been proposed 
to account for these effects, most notably S-nitrosylation [77].  S-nitrosylation is the 
addition of NO to a sulfur group predominantly occurring on cysteine residues of protein.  
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Recent in vitro data has demonstrated that NO can S-nitrosylate metallothionein (MT) 
increasing labile zinc in endothelial cells [73, 78].  In certain cell types, MT is bound to 
>30% of cytosolic zinc.  The interaction between MT and NO has been followed in real 
time using a fusion protein consisting of MT sandwiched between two mutant green 
fluorescent proteins [79].  In vitro studies with this protein demonstrated that observed 
fluorescent resonance energy transfer (FRET) changes are indicative of zinc release from 
MT.  Imaging experiments have found that agents that increase cytoplasmic Ca2+ act via 
endogenously generated NO to rapidly and persistently release zinc from MT, an effect 
that can be mimicked by NO donors or exogenous NO gas [79].  Further, utilizing the 
zinc-sensitive fluorophore, Zinquin ethyl ester (Alexis), it has been shown that the 
exposure of endothelial cells to NO donors results in a rapid increase in labile zinc [73, 
80, 81] and that the over-expression of MT can reduce this increase.
Heavy Metal Responsive Transcription Factor 1 (MTF-1) 
Zinc binding proteins are the most abundant class of protein in the human cellular 
proteome [82].  Therefore, in theory, liberating enough zinc from these protein 
interactions to activate zinc binding transcription factors without inducing apoptotic or 
necrotic cell death should be relatively easy.
Heavy metal responsive transcription factor 1 (MTF-1) is one such transcription 
factor of interest.  MTF-1 is a heavy metal-induced transcriptional activator [83-85] that 
is highly conserved from insects to vertebrates [86].  Targeted disruption of the MTF-1 
gene results in death at embryonic day 14 due to liver degeneration, revealing a stage-
specific developmental role [86].  Lichtlen et al. have engineered a mouse lacking 
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functional MTF-1 and discovered they die around day 14 of gestation due to acute decay 
of hepatocytes.  Since MTF-1 conditional knock outs have not been developed yet, 
evidence of functional deficits in the vascular system alone are unknown.  Also, under 
hypoxic-anoxic stress, MTF-1 helps to activate the transcription of the gene placental 
growth factor (PIGF), an angiogenic protein [86]. 
MTF-1 functions as a cellular zinc sensor, which coordinates the expression of 
genes involved in zinc homeostasis, as well as affording protection against metal toxicity 
and oxidative stress [87].  MTF-1 induces the expression of MT genes, which have the 
potential to act as chelators of heavy metals and scavenger of free radicals [88].  The 
current model suggests that the seven zinc-finger domain of MTF-1 directly and 
reversibly binds to zinc [83, 89].  This metallo-regulatory protein then adopts a DNA-
binding conformation and translocates to the nucleus, where it binds to metal-responsive 
elements (MREs) in these gene promoters leading to increased transcription [87, 90].  
Many genes contain putative MTF-1 binding sites that have been detected in the 
promoter sequences.  These include MT itself [91], the zinc-transporter-1 (ZnT1) [92], 
and the gamma-glutamylcysteine synthetase heavy chain [93].  In addition, it has been 
shown that physiologic levels of NO can induce glutathione synthesis (GSH) in ECs and 
that this appears to be mediated via an increase in cGMP independent gamma-
glutamylcysteine synthetase expression [94].
The mechanism by which zinc elicits MTF-1 conformational change, 
translocation to the nucleus, and synthesis of MT in a cell-free system has been outlined 
in a study by Zhang, et al. [72]. Hydrogen peroxide and certain heavy metals, such as 
cadmium, can disrupt zinc bound to MT.  Being the so-called zinc sensor of the cell, 
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MTF-1 binds the free zinc that is released and becomes activated by undergoing a 
conformational change.  Next, MTF-1 translocates to the nucleus, where it can act as a 
transcription factor and bind to various MREs, including MT.  Zhang suggests that newly 
produced “apo-metallothionein” (non-zinc containing MT) will bind up free zinc, thus 
acting as a basic regulatory mechanism for activation of MTF-1 during cellular stress.
These MREs are DNA sequence motifs with the consensus binding site 
TGCRCNC.  MREs are present in a number of genes’ promoters including 
metallothionein (MT) [95-97], the zinc transporter ZnT1 [92, 93, 98], and -
glutamylcysteine synthetase heavy chain [93, 98].  Upon liberation of labile zinc, the 
eNOS HRE could be a likely target of MTF-1 binding.  There are a limited number of 
studies that have explored the involvement of MTF-1 in the regulation of eNOS.   We 
hypothesized that NO generation and ROS production increase cellular free Zn and 
activate MTF-1.  This in turn causes MTF-1 nuclear translocation and increased 
expression of eNOS via the MRE located in the 5’-flanking region of the eNOS gene.
Endothelial cells in culture 
Since our interest is in the regulation of eNOS activity and gene expression in the 
pulmonary system, a tractable model is needed.  Thus, primary cultures of arterial 
endothelial cells from sheep and cow have been isolated and maintained in culture.  
These cells were obtained by scraping the main pulmonary artery and resistance vessels 
(<200 M).  After a few days in culture, moderate-sized aggregates of cells were 
transferred using a micropipette, grown to confluence and maintained in culture.  These 
cells take several passages to reach purity and can grow up to 20 passages before 
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reaching senescence.  They exhibit contact inhibition, are tightly opposed, and are 
cobblestone in appearance.
Research Significance
It is critical to understand the mechanisms by which eNOS is regulated, not only 
to identify the pathways 
responsible for the regulation of 
eNOS, but also to develop new 
treatments for PPHN. Certainly, 
a large body of work has been 
published in the regulation of 
eNOS in the cell, but in reality, 
still very little is known about 
the exact mechanisms of eNOS 
regulation.  It is likely that 
insights into the mechanisms of 
eNOS regulation are impeded by 
the fact that eNOS expression and 
regulation appear to vary in different 
EC cell lines.  Little or no thought is given to the source of endothelial cell used in most 
studies.  Thus, studies are published using cells isolated from a variety of different 
species that are isolated from a variety of different tissues.  These studies will utilize low 
passage ovine or bovine aortic endothelial cells.
Figure 6.  Hypothesized research pathway 
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We hypothesized that NO and ROS may be regulating eNOS expression and 
activity indirectly through their ability to alter cellular levels of free Zn.  Further, we 
hypothesized that Zn exerts an effect on eNOS at the transcriptional and post-
translational levels.  These novel hypotheses will be tested in the four chapters of this 
dissertation.
Results from these studies indicated that non-toxic, low dose NO and H2O2 up-
regulated eNOS promoter activity, mRNA, and total protein through the release of 
intracellular zinc, activation of MTF-1, and binding of MTF-1 to the eNOS HRE.  The 
direct addition of low micro-molar amounts of zinc caused a dose-dependent increase in 
eNOS dimer levels and also significantly increased eNOS activity and total protein 
levels, mainly through activation of MTF-1.  At higher levels it is associated with a large 
increase in ROS production.  High levels of ROS significantly decreased eNOS activity 
by enzyme fragmentation.  The eNOS cofactor, tetrahydrobiopterin (BH4), one of the 
most potent naturally occurring reducing agents, was found to help protect eNOS protein 
levels and activity by acting as an antioxidant.
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ABSTRACT 
Persistent pulmonary hypertension of the newborn (PPHN) poses a serious health 
risk for the newborn, afflicting 5 in 1000 each year.  The development of PPHN has been 
linked to a decrease in the activity and expression of the enzyme endothelial nitric oxide 
synthase (eNOS).  Unpublished studies from our lab indicated that eNOS expression and 
activity correlated with cellular levels of labile zinc (Zn).  In addition, our analysis of the 
eNOS promoter indicates the presence of a putative heavy metal response element (HRE) 
on the 5’-flanking sequence.  Thus, this study sets out to define the mechanism by which 
zinc mediates eNOS expression at the transcriptional level and eNOS activity at the post-
translational level.  Low passage (P4-P6) fetal pulmonary aortic endothelial cells 
(FPAECs) were exposed to 0, 25, 50, and 100µM ZnCl2 for 7hrs, or to zinc-depletion 
conditions, by virally transducing with metallothionein 1 (MT-1) adenovirus.  Zinc 
exposure led to increases in eNOS dimer and total protein levels and eNOS activity as 
measured by nitric oxide (NO) production.  It also activated the heavy metal responsive 
transcription factor 1 (MTF-1), causing a nuclear translocation of an MTF-1-GFP 
construct and binding to the eNOS promoter.  Transduction with MT-1 decreased MTF-1 
nuclear localization with or without the addition of zinc.  It also led to decreased eNOS 
promoter activity.  In summary, our results indicate that basal zinc levels are responsible 
for maintaining eNOS promoter activity and total protein levels, but once eNOS dimer is 
formed that it can withstand zinc depletion conditions.  We propose that supplementation 
with zinc may help minimize symptoms of PPHN by increasing eNOS levels and activity 
prior to birth.
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INTRODUCTION
The fetal to newborn transition is associated with a 10-fold increase in blood flow 
to the lungs and is dependent on the functioning of the enzyme endothelial nitric oxide 
synthase (eNOS).  However, in a number of clinical conditions, there is a failure of the 
pulmonary circulation to undergo the normal transition to postnatal life, resulting in 
persistent pulmonary hypertension of the newborn (PPHN).  PPHN is a serious disease 
that is thought to be responsible for approximately 10% of admissions to neonatal 
intensive care units and affects  5 in 1000 newborns each year [1].  The disorder is 
associated with significant morbidity and mortality [1].  The development of PPHN has 
been linked to a decrease in the activity and expression of eNOS.  Thus it is critical to 
understand the mechanisms by which eNOS is regulated in the perinatal period, not only 
to identify pathways responsible for the developmental regulation of eNOS, but also to 
develop new treatments for PPHN.           
In the vasculature, eNOS helps to maintain vascular homeostasis by generating 
nitric oxide (NO), which keeps the vascular resistance low, protects the intima of the 
vessels from platelet aggregation and leukocyte adhesion, and prevents proliferation of 
vascular smooth muscle.  Previously thought of as a constitutively expressed enzyme, it 
is now becoming more apparent that eNOS is dynamically regulated at the 
transcriptional, post-transcriptional, post-translational, and developmental levels.       
eNOS expression is largely tissue dependent, being predominantly expressed in 
endothelial cells, although studies have shown eNOS expression in bronchiolar epithelial 
cells [2, 3].  In recent years it has been shown that eNOS expression can be modulated by 
a variety of chemical, physical, and developmental stimuli.  Indeed, the eNOS promoter 
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contains a plethora of putative cis-elements, including Sp-1 and GATA motifs, a sterol 
regulatory element, estrogen-responsive elements, a nuclear factor 1 element, a cAMP-
responsive elements, and activator protein (AP-1 and -2) binding sites [4-6] that would 
allow eNOS to be regulated by many different signals.  Basal eNOS expression has been 
shown to be regulated in ECs by a complex interaction between two tightly clustered cis-
regulatory regions defined as positive regulatory domains I (-104/-95 relative initiation) 
and II (-144/-115) [7].  Our analysis of the eNOS promoter indicates the presence of a 
heavy metal response element (HRE) located at -899/-893 (TGCACTC) in the 5’-
flanking sequence of the human eNOS gene.  It is known that increases in zinc lead to 
increased activation of the heavy metal responsive transcription factor 1 (MTF-1), that 
binds to the HRE cis-elements [8].   Our initial studies indicated that the addition of 
exogenous zinc to endothelial cells significantly increased nitric oxide (NO) generation 
(ns). 
 Previously published research indicates that eNOS is only active as a dimeric 
enzyme and that the dimer is stabilized by the formation of a zinc tetrathiolate cluster, in 
which two cysteine thiolate ligands are contributed by each subunit [9-11].  When active 
and tightly coupled, eNOS produces NO. However, under certain conditions, NOS may 
generate reactive oxygen species (superoxide and hydrogen peroxide) rather than NO.
This process is referred to as NOS uncoupling, meaning that NADPH oxidation and NO 
synthesis have become uncoupled.  It is important to note that a series of in vitro
biochemical studies demonstrated that eNOS is the most tightly coupled of all the NOS 
isoforms [9-12] and definitive in vivo and in vitro evidence that uncoupling of eNOS can 
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occur is missing from the literature.  Thus, the mechanisms by which eNOS can become 
uncoupled in ECs are not completely understood. 
 In this study, we evaluated the effect of an acute zinc treatment on eNOS protein 
dimer levels, expression, and activity.   
 A large body of work has been published in the regulation of eNOS in the cell, 
but in reality, still very little is known about the exact mechanisms of eNOS regulation.  
The most important reason for this is that the majority of the data generated has been 
contradictory.  Indeed, it is likely that insights into the mechanisms of eNOS regulation 
are impeded by the fact that eNOS expression and regulation appear to vary in different 
EC cell lines.  Little or no thought is given to the source of endothelial cell used in most 
studies.  Thus, studies are published using cells isolated from a variety of different 
species and tissues.  Studies in this publication will utilize low passage (p4-p6) fetal 
pulmonary aortic endothelial cells (FPAECs).   
 MTF-1 functions as a cellular zinc sensor which coordinates the expression of 
genes involved in zinc homeostasis, as well as affording protection against metal toxicity 
and oxidative stress [13].  The current model suggests that the zinc-finger domain of 
MTF-1 directly and reversibly binds to zinc [14, 15].  This metallo-regulatory protein 
then adopts a DNA-binding conformation and translocates to the nucleus, where it binds 
to metal-responsive elements in these gene promoters leading to increased transcription 
[13, 16].  There are a number of genes in which putative MTF-1 binding sites have been 
detected in the promoter sequences, including metallothionein (MT) itself [17], the zinc 
transporter 1 (ZnT1) [18], and the gamma-glutamylcysteine synthetase heavy chain [19].
In addition, it has been shown that physiologic levels of NO can induce glutathione 
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synthesis (GSH) in endothelial cells (ECs).  This appears to be mediated via an increase 
in gamma-glutamylcysteine synthetase expression that is independent of cGMP [20].
However, no studies have explored the involvement of MTF-1 in the regulation of eNOS.
 We propose that the addition of zinc to FPAECs will activate MTF-1, causing 
nuclear translocation and binding to the HRE in the 5’-flanking region of the eNOS gene, 
which will increase eNOS protein expression.  Since zinc holds the eNOS homo-dimer 
together, the addition of zinc will also cause increases in eNOS activity as measured by 
NOx release.
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MATERIALS AND METHODS  
Cell Culture 
Primary cultures of ovine fetal pulmonary arterial endothelial (FPAECs) cells 
were isolated as detailed previously [21].  Endothelial cell identity was confirmed by 
their typical cobblestone appearance, contact inhibition, specific uptake of 1,1’-
dioctadecyl-1,3,3’,3’-tetramethyllindocarbocyanine perchlorate-labeled acetylated low-
density lipoprotein (Molecular Probes, Eugene, OR), and positive staining for von 
Willebrand factor (Dako, Carpentaria, CA).  FPAECs were grown in Eagles DMEM 
containing 1g/l glucose and phenol red (MediaTech, Herndon, VA), supplemented with 
10% fetal bovine serum (Hyclone, Logan, UT), and antibiotic-antimycotic (MediaTech).  
Cells were incubated at 37oC in a humidified atmosphere of 95% air and 5% CO2.  Cells 
were used at passage 4-6.  Zinc treatments were conducted in serum-free, phenol red free 
(SFPRF) media (MediaTech).  Prior to experimental treatment (unless otherwise noted) 
cells were trypsinized, counted with a hemacytometer and replated in a 6, 24-, or 96-well 
plate (Costar, Corning, NY) at densities of approximately 104/cm2 and allowed to adhere 
for at least 18hrs. 
Cell Death Analysis 
 FPAECs were cultured in 24-well plates and treated with various doses of zinc 
chloride or a vehicle control in serum free phenol red free (SFPRF) media for a 7hr time 
period.  After the treatment period, the medium was collected and centrifuged for 5min at 
500Xg, and the supernatant stored at 4oC until assayed.  Relative cytotoxicity was 
quantified by measuring the release of the soluble cytoplasmic enzyme lactate 
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dehydrogenase (LDH) activity in the cell-free supernatant using a commercial kit 
(Rosche Applied Science, Indianapolis, IN).  Briefly, in a fresh 96-well plate, 50µL 
aliquots of the cell-free medium and 50uL of reconstituted substrate mix were added to 
each well.  The plate was put in a plate reader (keeping the plate in the dark at room 
temperature) and absorbance readings at 490nm were taken over 40min at 10min 
intervals.  Each sample was measured in triplicate, with a minimum of three samples per 
experimental group.  Relative toxicity was determined by comparison of absorbance of 
the experimental group with absorbance of a control cell group treated with 1% Triton X-
100 cell lysis buffer according to the manufacturer’s protocol. 
Fluorescence Microscopy 
 A computer-based imaging system consisting of an Olympus IX51 microscope 
equipped with a charge-coupled device camera (Hamamatsu Photonics, Hamamatsu City, 
Japan) was used for acquisition of fluorescent images.  Fluorescent-stained cells were 
observed with the appropriate excitation and emission, and the average fluorescent 
intensities (Integrated Optical Density or mean IOD) were quantified using ImagePro 
Plus imaging software (version 5.0, Media Cybernetics, Silver Spring, MD).  Fluozin 3-
AM (Molecular Probes), a fluorescent dye specific for the unassociated Zn2+, was used 
for labile zinc imaging.  These were analyzed at 494-nm excitation and 516-nm emission.  
MTF-1-GFP nuclear translocation studies measured fluorescence at a 393-nm excitation 
and 509-nm emission.    
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eNOS Promoter Luciferase Activity Assay 
1.6kb eNOS promoter constructs were generated by polymerase chain reaction 
(PCR) using human genomic DNA as a template. The reverse primer common to all 
constructs binds immediately upstream of the ATG initiation codon of eNOS (5’ –
GTTACTGTG CGT CCA CTCTGCTGCC). The forward primer was 5’ – 
TGTAGTTTCCCTAGTCCCCC (840bp fragment).  A 3-bp mutation was introduced into 
the metal response element sequence within the 840bp construct.  The sequence -902 at -
890 in the human eNOS promoter was changed to GCAattACTCTGG by site-directed 
mutagenesis.
FPAECs were grown to 70% confluence and dually transfected with 0.4µg -gal
(internal control) and 1.6µg eNOS promoter-luciferase construct using Effectene 
transfection kit (Qiagen, Velencia, CA). 
 Plates were rinsed with DPBS and 200µL 1X Reporter Lysis Buffer (Promega, 
Madison, WI) was added to each well.  Plates were sealed with parafilm and frozen at -
800C for 20min or until later analysis.  Next, plates were taken out of the -80 and put in a 
370C incubator for 30min.  Plates were vortexed for 30s and cell solution was transferred 
to a new eppendorf tube.  This tube was vortexed for an additional 15s and then spun at 
14,000rpm for 10min at room temperature.  The supernatant was transferred to a new set 
of tubes and put on ice until analysis.   
 To normalize for transfection efficiency, -gal activity was measured first.  
Briefly, 5-10µL cell lysate was combined with 40-45µL 1X Reporter Lysis Buffer and 
50µL -gal substrate (Qiagen, Velencia, CA) for 100µL total.  The 96-well plate was 
then allowed to incubate at 370C for 30min.  Lastly, readings were taken on a Multiscan 
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plate reader at 405nm throughout the 30min incubation period as the substrate reacts with 
-gal.
 Luciferase activities were measured one sample at a time on a Fluoroscan plate 
reader set as a luminometer.  20µL of cell lysate was combined with 100µL luciferase 
substrate (Qiagen, Velencia, CA) and a reading on the luminometer was taken 
immediately.   
Protein Extraction 
FPAECs were grown to confluence on 6-well plates.  Cells were treated with 
various doses of zinc or a vehicle control in SFPF media for 7hrs.  Following treatment, 
cells were rinsed with DPBS (MediaTech) and RIPA lysis buffer added to each well.  
Cell were then collected and sheared with a 25-gauge needle 3X.  Lastly, samples were 
spun at 14,000Xg for 10min and the supernatant was collected.  Protein concentrations 
were analyzed using Bio-Rad protein assay (Bio-Rad, Hercules, CA) and Bovine Serum 
Albumin (BSA) for the protein standard curve.
Western Blotting 
Western Blot analysis was performed as previously described [21].  Total protein 
extracts (~20µg) were resuspended in 5X Laemmli protein sample buffer and boiled for 
5min.  Total protein was then separated on a 4-20% Tris-SDS-HEPES polyacrylamide 
gel (Gradiopore, Frenchs Forest, Australia) and electrophoretically wet-transferred to a 
Hybond-PVDF membrane (Amersham, Arlington Hts., IL).  The membranes were 
blocked with 5% nonfat dry milk in Tris buffered saline containing 0.1% Tween-20 
25
(TBST) overnight at 40C.  After blocking, the membranes were incubated at room 
temperature for 2 hrs with the primary antibody (1:1,000 for -eNOS, BD Biosciences), 
washed 3X with TBST, and incubated with a mouse anti-rabbit IgG-horseradish 
peroxidase conjugated secondary antibody (Pierce, Rockford, IL) for 1 hr.  After 
washing, immunolabeled protein bands were visualized using chemiluminescence 
(SuperSignal West Fempto Substrate Kit, Pierce) on a Kodak Image Station 440CF with 
Kodak 1D Molecular Imaging Software and normalized to immunolabeled -actin 
(1:1000, Sigma) on the same blot. 
Low Temperature Poly Acrylamide Gel Electrophoresis (LT-PAGE) 
 LT-PAGE was used to analyze eNOS dimer levels.  Briefly, cells were treated 
with zinc or a vehicle control in SFPF media for 7hrs and then were rinsed 2X with 
DPBS.  Cells were harvested and protein concentrations measured as stated in the 
Western Blot section above.  However, samples were not boiled as in a regular Western 
Blot prior to loading.  Equal protein was loaded onto a denaturing Polyacrylamide gel 
and run on ice at 30v for approximately 7hrs.  Transfer, blocking, and probing were 
performed similar to the Western Blot method above.      
Assay for NOS Activity
NOS activity was determined by measuring NOx levels in the media using a NOx
specific probe (Apollo 4000 Free Radical Analyzer, World Precision Instruments, Inc.).  
Briefly, following treatment with zinc or a vehicle control, media was collected and NOx
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levels were measured.  Potassium Nitrate solutions, made in media, were used to make a 
standard curve for determining NOx levels. 
Generation of MT-1 Adenoviral Expression Construct 
An adenoviral vector expressing MT-1 was constructed with the pAd/pENTR 
System (Invitrogen) [22].  Briefly, a pAd/CMV plasmid containing an MT-1 cDNA 
(cDNA purchased from ATCC, Manassas, VA) was created and transfected into 293A 
cells.  A selected clone was propagated and viral lysates were collected and titered per the 
manufacturer’s protocol.  The titer for the AdV.MT-1 preparation was 3.4e1010 plaque-
forming units per mL.  Infections on PAECs were performed for 120min with virus 
diluted in normal DMEM to the desired multiplicity of infection.  Verification of 
transgene expression was performed using Western Blot analysis as described above 
using 20µg of protein extracts.
Quantification of Intracellular Zn2+ Levels 
 FPAECs were grown on glass cover slips in 6-well plates and treated with various 
doses of zinc chloride or a vehicle control in SFPF media for 1hr at 370C.  After a 30min 
treatment, cells were loaded with 2.5µM Fluozin 3-AM (Molecular Probes), a fluorescent 
dye specific for the unassociated Zn2+.  Following the treatment period, cells were 
washed twice with SFPRF media and incubated for an additional 30min in the dark at 
37oC (in the incubator).  Cell-coated glass cover slips were removed from the 6-well plate 
one at a time and put onto a glass slides.  These slides were analyzed by fluorescent 
microscopy as described above.    
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MTF-1-GFP Nuclear Translocation 
 MTF-1 and GFP constructs were cloned into the pcDNA 3.1-Hygro (+) vector, 
and enzymatic digests were utilized to verify cloning products and their orientation.  
FPAECs were grown on glass cover slips in 6-well plates to 50-60% confluence, and 
were transfected with the MTF-1-GFP construct using Effectene transfection reagent 
(Qiagen, Valencia, CA).  MTF-1-GFP translocation was determined using fluorescent 
microscopy as described above.  A higher mean IOD correlated to more nuclear 
localization.  A minimum of 3 field pictures were taken per well and averaged.  The mean 
± standard deviation was calculated and a P<0.05 was considered statistically significant 
from the control.   
Statistical Analysis
Values are expressed as the means ± standard error of the mean from at least three 
experiments.  Statistical analysis between experimental groups was performed by one 
way ANOVA or T-test using the Graph Pad Prism 4.0 statistical analysis software 
program.  A P < 0.05 was considered statistically significant. 
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RESULTS
Our initial experimental data for this publication evaluated the developmental 
differences in enzyme endothelial nitric oxide synthase (eNOS) protein and activity 
levels.  Passage matched fetal (FPAECs) and adult pulmonary aortic endothelial cells 
(AdPAECs) were grown to confluence in regular DMEM media.  Media was collected 
for NOx levels and protein was harvested for eNOS levels.  Results indicated that eNOS 
protein levels were 5-6 fold higher in fetal versus adult PAECs (not shown).  This data 
correlated with previous studies from our lab indicating that eNOS expression is higher in 
the fetal stage and then decreases in the adult.  However, NOx generation was nearly 20-
fold higher in FPAECs versus AdPAECs (data not shown).  This suggests that eNOS is 
more tightly coupled in the fetal stage compared to the adult.  Interestingly, 
developmental cellular free zinc levels from these cells correlated with eNOS expression, 
such that free zinc levels were nearly 2-fold higher in the fetal compared to the adult cells 
(data not shown).  In addition, our analysis of the eNOS promoter indicated the presence 
of a putative heavy metal response element (HRE) on the 5’-flanking sequence. This led 
us to explore the role of zinc in eNOS regulation.
We wanted to determine whether modulating cellular zinc would alter eNOS at 
the transcriptional and post-translational levels in FPAECs.  The development of 
persistent pulmonary hypertension of the newborn (PPHN) has been linked to a decrease 
in the activity and expression of eNOS.  FPAECs were used instead of adult cells for 
these studies, since they are the cells that are intimately involved in the transition of a 
baby at birth.
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We first determined whether the addition of exogenous zinc would increase eNOS 
dimer levels.  FPAECs were treated with 0 and 50µM zinc chloride (ZnCl2) for 0-9hrs.
Protein was harvested from the cells.  Low Temperature Polyacrylamide Gel 
Electrophoresis (LT-PAGE) and Western Blot analysis was used to examine eNOS 
protein dimer levels (data not shown).  Following a 7hr zinc treatment, eNOS protein 
dimer levels dose dependently increased.  We then set up another experiment using a 7h 
ZnCl2 treatment of 0-100µM.  Results indicated a dose dependent increase in eNOS 
dimer levels peaking at 25 and 50µM ZnCl2 (Figure 1) and dropping off at the nontoxic 
(Lactate Dehydrogenase (LDH) release, data not shown) dose of 100µM .
Next we wanted to determine whether the 7hr ZnCl2 treatment inceased total 
eNOS protein levels.  Western Blot analysis was carried out on the protein extracts from 
the first experiments in FPAECs and blots were probed with anti-eNOS.  Total eNOS 
protein levels following zinc 7h treatment were not statistically different from the 0µM 
ZnCl2 control (data not shown).  Therefore, FPAECs were treated for 20hrs with the same 
doses of ZnCl2 and protein was harvested.  At the 20hr time point, eNOS protein was 
statistically higher than control in both the 25 and 50µM treatments (Figure 2).   
To determine whether these zinc treatments were causing increases in levels of 
cellular free zinc, the cell permeable zinc fluorophore, Fluozin-3 AM, was used.
FPAECs were grown on glass cover slips and were treated with ZnCl2 for 1hr, rinsed, and 
loaded with Fluozin-3 AM.  Fluorescent photographs were taken with an Olympus 
microscope using a GFP cube and quantitated with the Image Pro software.  Zinc levels 
were significantly higher (p<0.05) in the 25, 50, and 100µM ZnCl2 treatments (Figure 3).    
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We next looked to see if eNOS activity as measured by NOx release correlated 
with the increased levels of eNOS dimer and total protein levels.  FPAECs were treated 
for 7hrs with ZnCl2.  Shear is known to activate eNOS; therefore as a positive control for 
increased eNOS activation, we used 15min shear on half of the samples in this 
experiment prior to analyzing NOx levels.  Shearing was accomplished with a shear plate 
viscometer at a level that is comparable to shear forces seen in vivo.  Media was collected 
and immediately analyzed for NOx levels using a NOx specific membrane covered micro-
probe system.  eNOS activity was significantly higher (p<0.05) in the 25, 50, and 100µM 
ZnCl2 treatments in both un-sheared and sheared cells (Figure 4).
The addition of exogenous zinc increased cellular free zinc levels, therefore, we 
wanted to determine the effect of this zinc on the nuclear translocation of heavy metal 
responsive transcription factor 1 (MTF-1).  FPAECs were grown on glass cover slips in 
6-well plates to ~60% confluence and then transfected with a MTF-1-GFP construct.
After 24hrs, cells were treated for ~1hr with various doses of ZnCl2.  As described above, 
fluorescence microscopy and Image Pro software were used for analysis.  Integrated 
Optical Density (IOD) was used to determine the average fluorescent intensity for each 
cell.  A higher average correlates to increased MTF-1 nuclear localization.  Average 
nuclear brightness per well was determined by averaging the three random fields.
Concentrations of 25, 50, and 100µM ZnCl2 all increased MTF-1-GFP nuclear 
translocation (Figure 5).
Next, we determined if depleting zinc, by virally transducing with 
metallothionein-1 (MT-1), would prevent basal MTF-1 nuclear localization.  FPAECs 
were grown on glass cover slips in 6-well plates and transduced (MOI=1000) with either 
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a Lac Z viral control or MT-1 adenovirus. After 24hrs, cells were transfected with the 
MTF-1 GFP construct.  Following an additional 24hrs, cells were exposed to 50µM 
ZnCl2 for 1hr.  Nuclear localization was scored similar to the previous experiment.  As in 
untransduced cells, Lac Z transduced cells exhibited increased MTF-1 nuclear 
localization following zinc treatment (Figure 6).  MT-1 significantly (p<0.05) decreased 
MTF-1 nuclear localization basally and prevented the increase following zinc treatment 
(Figure 6).
 Treating FPAECs with zinc increased total eNOS protein, so we next wanted to 
determine the affect of cellular zinc depletion with MT-1 transduction on total eNOS 
protein expression.  FPAECs were grown to ~80% confluence and transduced with GFP 
or MT-1 adenovirus (MOI=1000).  After 36hrs, protein was harvested and Western Blot 
analysis was used to measure total eNOS protein.  MT-1 expression caused a significant 
decrease in total eNOS protein (Figure 7).
Our data indicated that the addition of zinc increased eNOS dimer levels, so we 
next looked at the effect of depleting zinc on eNOS dimer levels.  Using protein extracts 
from the previous experiment, LT-PAGE and Western Blot analysis were used to analyze 
eNOS dimer levels.  Interestingly, eNOS dimer/monomer ratio did not decrease with MT-
1 transduction (data not shown).
Results showing that the addition of zinc increased eNOS protein levels and the 
depletion of zinc decreased eNOS protein levels, suggested that the addition of zinc to 
FPAECs would increase eNOS transcription.  Constructs were made combining a 
luciferase reporter sequence with a 5’ eNOS regulatory element (-840 to 0).  Both a wild 
type (WT) and a metal response element (MRE)-mutated eNOS luciferase construct were 
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utilized.  The WT construct was compared to a construct containing the mutation in the 5’ 
regulatory region from -902 to -890, corresponding to the MRE.  A -gal construct was 
also made to use as a transfection control.  FPAECs were co-transfected with either a WT 
or mutant eNOS promoter luciferase and a -gal construct.  24hrs later, cells were treated 
for 7hrs with ZnCl2. -gal and luciferase expression were measured by adding their 
respective substrates and reading on a plate reader or luminometer, as detailed above.  
Treatment of FPAECs with 50µM ZnCl2 resulted in significantly increased eNOS 
luciferase activity in the WT transfectants (p<0.05) (Figure 8 A).  However, there was no 
significant increase in luciferase activity in FPAECs transfected with the MRE-mutated 
construct (p<0.05) (Figure 8 B).
Since eNOS luciferase data suggested that zinc-dependent increases in eNOS 
transcription are MRE dependent (Figure 8), the next step was to determine what 
transcription factors are involved.  FPAECs were transduced with a GFP viral control or 
a MT-1 adenovirus (MOI=1000).  After 36hrs, cells were harvested and nuclear protein 
extracts were made.  Bandshift analysis was used to determine if the transcription factors 
Sp-1 or MTF-1 were responsible for the zinc-dependent binding of eNOS promoter 
basally in FPAECs.    Results indicate that overexpression of MT-1 affects the binding of 
the eNOS regulatory sequence by both SP-1 and MTF-1.  It significantly decreases SP-1 
binding by 35% (Figure 9 A & B), but to a greater extent, significantly decreases MTF-1 
binding by 55% (Figure 10 A & B).
MTF-1 is a major zinc responsive transcription factor involved in basal eNOS 
transcription (Figure 10).  Decreased the amount of cellular zinc available by 
transduction with MT-1 significantly decreased MTF-1 binding to the eNOS regulatory 
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domain (Figure 10), therefore, we next determined if treating FPAECs with ZnCl2 would 
increase MTF-1 binding to the eNOS regulatory domain.   FPAECs were treated with 
ZnCl2 for 7hrs and nuclear protein extracts were made.  These extracts were used for 
bandshift analysis to determine the effect on MTF-1 binding.  Results indicated that 
treatment with ZnCl2 increased MTF-1 binding to eNOS regulatory domain at both 25 
and 50µM ZnCl2 (Figure 11) in the three separate experiments.   
To be sure that the band observed in Figures 10 and 11 is from MTF-1 binding, 
we used a supershift assay.  Nuclear extract from untreated FPAECs were incubated with 
either 2 or 4µL -MTF-1 antibody at 40C overnight.  Bandshift analysis was then 
performed on this extract.  If MTF-1 was bound to the eNOS regulatory sequence DNA, 
then the MTF-1 antibody should bind to that MTF-1/DNA complex, increasing its 
molecular weight and shifting it up on the gel.  Results indicate that a supershift occurred 
with both 2 and 4µL of MTF-1 antibody in the upper band (Figure 12).
To be sure that MTF-1 was binding to the MRE in the eNOS 5’ regulatory 
sequence DNA, we mutated three bases in the MRE of the eNOS regulatory domain 
construct.  Bandshift analysis was performed using untreated FPAEC nuclear extracts and 
the mutated MRE eNOS regulatory sequence DNA.  Results found 45% decrease in 
MTF-1 binding with the mutated MRE eNOS 5’ regulatory sequence DNA compared to 
WT (Figure 13).
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DISCUSSION 
In this study, we provide evidence of a pathway by which the addition of 
exogenous zinc in endothelial cells drives increases in endothelial nitric oxide synthase 
(eNOS) protein dimer, total eNOS protein, and eNOS activity.  These increases are 
mainly due to the activation, nuclear localization, and binding of the heavy metal 
responsive transcription factor 1 (MTF-1) to the eNOS metal response element (MRE).  
Developmental studies found that eNOS protein and activity levels correlated with 
cellular labile zinc levels, which led us to further explore the regulation of eNOS by zinc.  
Our studies established that exposure of fetal pulmonary aortic endothelial cells 
(FPAECs) to exogenous ZnCl2 results in: (1) Immediate increases in intracellular zinc, 
(2) Phasic increases in eNOS protein dimer levels, (3) Increases in total eNOS protein, 
(4) Increases in eNOS promoter luciferase activity, and (5) Enhancement of MTF-1 
nuclear translocation and binding to the eNOS promoter.  Depletion of basal zinc levels 
in the FPAECs by viral transduction with MT-1 adenovirus, produced decreases in total 
eNOS protein and MTF-1 nuclear translocation with no change in eNOS dimer levels.  
As a result, we conclude that our data proposes a role of zinc homeostasis in eNOS 
transcriptional and post-translational regulation mainly occuring through MTF-1 
activation.
Initially, we verified data indicating that FPAECs have higher eNOS expression 
compared to AdPAECs.  The results indicated that there was 2-fold higher eNOS protein 
in FPAECs versus AdPAECs (Figure 1). However, FPAECs produced nearly 20-fold 
higher NO versus AdPAECs, demonstrating that eNOS in FPAECs is much more tightly 
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coupled and active (data not shown).  This agrees with previous studies from our 
laboratory [23].   
Pitt and colleagues have carried out elegant studies indicating that NO donors can 
induce an increase in labile zinc in adult ovine PAECs [24, 25].  At least part of the 
mechanism of this labile zinc increase is S-nitroslation of metallothionein (MT) by NO 
[13, 25, 26].  However, it is unknown if there are developmental differences in basal 
levels of labile zinc in ECs.  Thus, our studies examined the labile zinc levels in ECs 
isolated from fetal and adult sheep.  Since, fetal endothelial cells produce much higher 
NO compared to adult, the results obtained here indicated that zinquin fluorescence levels 
were 2-fold higher in fetal (ns), correlating well with Pitt’s studies.  The levels of labile 
zinc also correlated with eNOS protein levels, such that FPAECs had 2-3-fold higher 
compared to adult (ns), suggesting that NO production may be driving eNOS 
transcription through the release of free zinc.
A recent paper that we published explored alterations in zinc homeostasis that 
lead to cell toxicity and induction of apoptosis [27], however these utilized doses of zinc 
(250µM and greater) that were much higher than doses used here and caused induction of 
ROS production.  These studies selected doses and time courses of ZnCl2 treatment that 
were non-toxic in FPAECs.  While certain compounds, most notably the zinc ionophore 
pyrithione [28], have been shown to enhance ZnCl2 uptake into cells, we found adverse 
toxicity of the compound in FPAECs and therefore, precluded its use for these studies. 
The doses of ZnCl2 used here (25-100µM) increased intracellular zinc levels within 
15min as measured by Fluozin-3AM fluorescence (data shown for 1hr in Figure 3), 
therefore no zinc ionophore was necessary.
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To date, a diverse set of physiological, nutritional, and biochemical functions 
have been attributed to zinc [29].   Zinc atoms are positioned at catalytic, structural and 
regulatory sites of enzymes (e.g. caspase-3, superoxide dismutase, NO synthase), 
transcription factors (TFIIIA) and structural proteins accounting for its importance in 
maintaining a wide variety of biological processes [30].  Pathologies linked to Zn2+
deficiency are well documented [31], and sufficient dietary uptake of zinc remains a 
nutritional issue of global dimensions [32]. 
Since zinc plays an integral role in the eNOS homodimer, linking the two 
monomers by a zinc tetrathiolate cluster, we determined whether the addition of zinc to 
fetal pulmonary aortic endothelial cells would increase eNOS dimer levels.  After testing 
various doses and time courses, it was determined that the passage and lot of FPAECs 
used in this study responded to a 7hr ZnCl2 exposure with increased eNOS dimer and 
total protein levels at 25 and 50µM followed by a decrease at 100µM (Figure 3).  This 
indicated that the addition of zinc to FPAECs does increase eNOS dimer protein levels 
and supports the hypothesis that eNOS is regulated by zinc.
Zinc is very tightly regulated in the cell, as intracellular concentrations of Zn2+
ions have been measured in pico- or nanomolar concentrations [33], indicative of the 
requirement for strict sequestration.  Metallothioneins (MT) are a family of proteins 
containing 20 cysteine residues and thus, play a crucial part in zinc homeostasis within 
mammalian cells.  In fact, MT is believed to bind 5-10% of the total mammalian cellular 
zinc [34].  MT binds more tightly to zinc than other zinc binding proteins and it is 
believed to participate in intracellular signal transduction pathways via the regulation of 
37
intracellular zinc trafficking and homeostasis, utilizing thiolate clusters within the MT 
protein [35].
SP-1 is ubiquitously expressed zinc-responsive transcription factor.  The eNOS 
promoter does contain an SP-1 binding site at -103 that has been found to be necessary 
for basal eNOS transcription in endothelial cells [36], so it was expected to see that SP-1 
played a role in the basal zinc dependent regulation of eNOS (Figure 14). 
The zinc-sensitive, heavy metal response element binding transcription factor, 
MTF-1 plays a central role in transcriptional activation of MT gene in response to heavy 
metals and oxidative stress [8, 14].  Our analysis of the eNOS promoter indicated the 
presence of a putative heavy metal response element (HRE) located at -899/-893 in the 
5’-flanking sequence of the human eNOS gene.  As expected from studies in other cell 
types, the addition of ZnCl2 to FPAECs resulted in increased nuclear translocation of 
MTF-1-GFP (Figure 8).  To determine whether MTF-1 was involved in the regulation of 
eNOS, we next performed MTF-1 bandshift analysis.  It was interesting to see that MTF-
1 also seemed to be very critical for basal zinc dependent eNOS regulation.  MTF-1 does 
work together with MT, the zinc sink in the cell; therefore we believe that it is a key 
transcription factor involved in the zinc dependent regulation of eNOS.
In summary, this study establishes a link between cellular zinc homeostasis and 
eNOS protein and activity.  In lower doses, zinc can stimulate enzyme levels and activity 
and at higher doses, it can cause decreases in enzyme levels and activity.  This data 
suggests that maintaining certain dietary levels of zinc could be important in maintaining 
endothelial function and that zinc supplementation during pregnancy may help minimize 
symptoms PPHN by increasing eNOS levels and activity prior to birth.   
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FIGURE LEGENDS 
Fig. 1.  A 7hr treatment with ZnCl2 leads to an increase in eNOS dimer levels.  FPAECs 
were exposed to ZnCl2 for 7hrs in SFPRF media.  LT-PAGE analysis indicated that 
eNOS dimer levels significantly increased at ZnCl2 doses of 10, 25, and 50µM.  All 
values are mean ± SEM (n=4). * P<0.05 vs. 0µM ZnCl2 treatment. 
Fig. 2.  A 20hr treatment with ZnCl2 leads to increases in total eNOS protein levels.
FPAECs were exposed to ZnCl2 for 20hrs in SFPRF media. Western blot analysis 
indicated that total eNOS levels increased at some doses of ZnCl2.  All values are mean ± 
SD (n=4). * P<0.05 vs. 0µM ZnCl2 treatment. 
Fig. 3.  A 1hr treatment with ZnCl2 leads to increases in cellular level of free zinc.
FPAECs were exposed to ZnCl2 for 1hr in SFPRF media.  Cells were rinsed and then 
loaded with 1µM Fluozin-3.  An Olympus fluorescent microscope with a GFP filter cube 
was used to take photographs.  Image Pro Software was used to quantitate fluorescence.
All values are mean ± SEM (n=5). * P<0.05 vs. 0µM ZnCl2 treatment. 
Fig. 4.  A 7hr treatment with ZnCl2 and shear both increased NOx production in FPAECs.
Sheared and unsheared FPAECs were exposed to increasing levels of ZnCl2 for 7hr in 
SFPRF media.  Sheared cells were exposed to flow stress with a shear plate viscometer 
for 15min.  Media was collected and NOx levels were analyzed using the NOII Analyzer.
All values are mean ± SEM (n=4). * P<0.05 vs. 0µM ZnCl2 treatment +/- shear. 
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Fig. 5.  The addition of zinc to FPAECs induces nuclear translocation of MTF-1-GFP.
FPAECs were transfected with MTF-1-GFP.  24hrs later, cells were treated for ~1hr with 
ZnCl2.  They were then visualized on an Olympus scope using a GFP cube. Nuclear 
localization is determined using Image Pro Software with a mean IOD measurement.  All 
values are mean ± SEM (n=4). * P<0.05 vs. 0µM ZnCl2.
Fig. 6.  A 1hr treatment with ZnCl2 leads to increases in MTF-1 nuclear localization, but 
is prevented by overexpression of MT-1.  FPAECs were transduced with Lac Z or MT-1 
adenovirus at MOI=1000.  After 24hrs, they were transfected with MTF-1 GFP and then 
24hrs later, they were exposed to 50µM ZnCl2 for 1hr in SFPRF media. An Olympus 
fluorescent microscope and GFP cube filter were used to take pictures of MTF-1-GFP 
localization and nuclear localization was quantitated using Image Pro Software with a 
mean IOD measurement.  All values are mean ± SEM (n=5). * P<0.05 vs. 0µM ZnCl2
treatment and Lac Z transduction. 
Fig. 7.  Overexpression of MT-1 leads to a decrease in total eNOS protein levels.
FPAECs were transduced with GFP or MT-1 adenovirus at MOI=1000.  After 36hrs, 
total protein was harvested and Western Blot analysis was used to measure total eNOS 
protein.  All values are mean ± SEM (n=3). * P<0.05 vs. GFP transduced sample. 
Fig. 8.  The addition of zinc to FPAECs leads to increased eNOS luciferase activity in 
WT, but not in the MRE-mutant.  FPAECs were co-transfected with either WT (A) or 
mutant (B) eNOS luciferase and a -gal constructs.  After 24hrs, cells were treated for 
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7hrs with 50µM ZnCl2. -gal and luciferase activities were assayed in FPAECs by 
adding their respective substrates and measuring absorbance on a plate reader for -gal 
and a luminometer for luciferase.  All values are mean ± SEM (n=9). * P<0.05 vs. 0µM 
ZnCl2.
Fig. 9.  Overexpression of MT-1 leads to a decrease in SP-1 binding to the eNOS 
regulatory region.  FPAECs were transduced with a GFP or MT-1 adenovirus 
(MOI=1000).  After 36hrs, nuclear protein extracts were made.  Bandshift analysis was 
performed with the nuclear extracts.  All values are mean ± SEM (n=3). * P<0.05 vs. 
GFP transduced sample. 
Fig. 10.  Overexpression of MT-1 leads to a decrease in MTF-1 binding the eNOS 
promoter.  FPAECs were transduced with GFP or MT-1 adenovirus (MOI=1000).  After 
36hrs, nuclear protein extracts were made.  .  Bandshift analysis was performed with the 
nuclear extracts.  All values are mean ± SD (n=3). * P<0.05 vs. GFP transduced sample. 
Fig. 11.  Treatment with ZnCl2 leads to increases in MTF-1 binding to eNOS promoter.  
FPAECs were treated with ZnCl2 for 7hrs and nuclear protein extracts were made.  .  
Bandshift analysis was performed with the nuclear extracts.  All values are mean ± SEM 
(n=3). * P<0.05 vs. 0µM ZnCl2 transduced sample. 
Fig. 12.  Supershift occurs with both 2 and 4 µL MTF-1 antibody.  FPAEC untreated 
nucleear extract is mixed with 0, 2, or 4µL MTF-1 antibody and allowed to react 
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overnight at 40C.  Bandshift analysis was performed on reaction mixtures of MTF-1 
antibody/eNOS 5’ regulatory domain sequence DNA.   
Fig. 13.  Mutating the eNOS MRE causes a 45% decrease in MTF-1 binding. Bandshift 
analysis of untreated FPAEC nuclear extracts, utilizing an MRE-mutant eNOS 5’ 
regulatory domain were performed.  All values are mean ± SD (n=3). * P<0.05 vs. WT 
oligo sample. 
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ABSTRACT 
Although endothelial nitric oxide synthase (eNOS) was originally thought to be a 
constitutively expressed enzyme, in recent years it has become clear that it’s expression 
can be modulated by a variety of chemical, physical, and developmental stimuli.  Studies 
in our lab and others have shown that high doses of nitric oxide (NO) or hydrogen 
peroxide (H2O2) lead to decreases in eNOS expression and activity.  However, at lower 
doses of H2O2, we have seen increases in eNOS expression and activity.  Other studies 
have shown that NO donors lead to increases in eNOS expression and activity.   
Therefore, we set out determine whether the NO donor spermine NONOate and H2O2
stimulate eNOS activity and expression in bovine aortic endothelial cells (BAECs) by 
increasing cellular free zinc levels and activating heavy metal responsive transcription 
factor 1 (MTF-1).  Results indicated that BAECs stimulated for 1hr with either spermine 
NONOate or H2O2 had increased cellular labile zinc levels as indicated by Fluozin-3 AM 
fluorescence.  An 18hrs treatment with either spermine NONOate or H2O2 yielded
elevated levels of eNOS promoter activity, mRNA, and total protein levels.  Using 
bandshift analysis and metallothionein (MT-1) viral transduction, we determined that 
both treatments led to zinc dependent increases in MTF-1 binding to the eNOS promoter.  
In conclusion, NO and H2O2 both appear to activate eNOS in a zinc dependent manner by 
liberating cellular stores of zinc and activating MTF-1, which binds to a region of the 
eNOS promoter that contains a metal response element.     
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INTRODUCTION
Under normal birth conditions, with the initiation of ventilation in the lungs, 
pulmonary vascular resistance decreases and pulmonary blood flow increases 8- to 10-
fold  [1-3].  However, in some instances, the normal transition does not occur, resulting 
in persistent pulmonary hypertension of the newborn (PPHN).   The expression and 
activity of the enzyme endothelial nitric oxide synthase (eNOS), which is intimately 
involved in blood pressure control, is decreased in PPHN.
Originally thought to be a constitutively expressed enzyme, the regulation of 
eNOS has been demonstrated at the transcriptional, post-transcriptional and post-
translational levels [4-9].  It is now known that eNOS can be modulated by a variety of 
chemical, physical, and developmental stimuli [10].  Studies in our lab have shown that 
high doses of nitric oxide (NO) or hydrogen peroxide (H2O2) induce apoptosis and 
mitochondrial dysfunction in pulmonary aortic endothelial cells [11, 12] and can decrease 
eNOS expression and activity [13].
H2O2, most commonly produced when superoxide (O2.-) is dismutated by 
superoxide dismutase (SOD), is the most stable and long lasting of the ROS [14].  It has 
been previously shown that H2O2, but not O2.- or hydroxyl radicals (OH.), increase eNOS 
expression by increasing both the rate of transcription of eNOS gene and the stability of 
the eNOS message once it is formed [10].    H2O2 has the ability to s-nitrosylate protein 
thiols.  Previous studies carried out in a cell-free system have indicated that H2O2 releases 
zinc from metallothionein [15].  By exposing cells to certain levels of NO, either through 
exogenous NO [16, 17] or by upregulation of inducible nitric oxide synthase (iNOS) 
activity [18], studies have also demonstrated increases in intracellular labile zinc (Zn2+)
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levels.  Our laboratory has also previously demonstrated that maintaining zinc 
homeostasis is important in endothelial cell viability [11, 12]. 
We have previously shown that the addition of high levels of exogenous zinc to 
pulmonary aortic endothelial cells resulted in a dose dependent increase in ROS 
production, specifically O2.-, producing mitochondrial dysfunction and inducing apoptotic 
cell death [12].  Heavy metal responsive transcription factor 1 (MTF-1) is an intracellular 
zinc sensor that works hand-in-hand with the zinc sink of the cell, metallothionein (MT).  
Upon binding of zinc, MTF-1 undergoes a conformational change, translocates to the 
nucleus, and binds to DNA sequence motifs with the consensus binding site TGCRCNC, 
known as metal response elements (MREs).   
MREs are present in a number of genes’ promoters including MT itself [19-21], 
the zinc transporter ZnT1 [22-24], and -glutamylcysteine synthetase heavy chain [22, 
24].  Our analysis of the eNOS promoter indicated a putative MRE located at -899/-893 
(TGCACTC) in the 5’-flanking sequence of the eNOS gene.
Therefore, the objective of this study was to evaluate the signaling effects of low, 
near physiologic doses of NO, from the NO donor spermine NONOate, and H2O2 on the 
stimulation of eNOS.  We will then look specifically at the mechanism of this stimulation 
and if it’s due to NO and H2O2’s ability to affect zinc storage.  Results from this study 
indicated that non-toxic, low dose NO and H2O2 upregulated eNOS promoter activity, 
mRNA, and total protein through their ability to alter intracellular zinc levels and activate 
MTF-1, which then would bind to the eNOS MRE.
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MATERIALS AND METHODS  
Cell Culture 
Primary cultures of Bovine pulmonary arterial endothelial cells (BAECs) were 
generously donated by Dr. J. Douglas Coffin at the University of Montana.  Endothelial 
cell identity was confirmed by their typical cobblestone appearance, contact inhibition, 
specific uptake of 1,1’-dioctadecyl-1,3,3’,3’-tetramethyllindocarbocyanine perchlorate-
labeled acetylated low-density lipoprotein (Molecular Probes, Eugene, OR), and positive 
staining for von Willebrand factor (Dako, Carpentaria, CA).  BAECs were grown in 
Eagle DMEM containing 1g/l glucose and phenol red (MediaTech, Herndon, VA), 
supplemented with 10% fetal bovine serum (Hyclone, Logan, UT), and antibiotic-
antimycotic (MediaTech).  Cells were incubated at 37oC in a humidified atmosphere of 
95% air and 5% CO2.  Prior to experimental treatment (unless otherwise noted) cells were 
trypsinized, counted with a hemacytometer and replated in a 6, 24-, or 96-well plate 
(Costar, Corning, NY) at densities of approximately 104/cm2 and allowed to adhere for at 
least 18hrs. 
Cell Death Analysis 
 BAECs were treated in serum-free, phenol red-free (SFPRF) media for an 18hr 
time period with various doses of spermine NONOate, hydrogen peroxide (H2O2), or a 
vehicle control.  After the treatment period, the medium was collected and centrifuged for 
5min at 500Xg, and the supernatant was stored at 4oC until assay.  Relative cytotoxicity 
was quantified by measuring the release of the soluble cytoplasmic enzyme lactate 
dehydrogenase (LDH) activity in the cell-free supernatant using a commercial kit 
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(Rosche Applied Science, Indianapolis, IN).  Briefly, in a fresh 96-well plate, 50µL 
aliquots of the cell-free medium and 50uL of reconstituted substrate mix were added to 
each well.  LDH activity was determined spectrophotometrically using a Thermo 
Electron Multiscan by measuring absorbance at 490nm over a 40min period.  Each 
sample was measured in triplicate, with a minimum of three samples per experimental 
group.  Relative toxicity was determined by comparison of absorbance of all 
experimental groups with absorbance of a control cell group treated with 1% Triton X-
100 cell lysis buffer according to the manufacturer’s protocol.  This experiment was 
performed six separate times for H2O2 and twelve for spermine NONOate.   
Fluorescence Microscopy 
 A computer-based imaging system consisting of an Olympus IX51 microscope 
equipped with a charge-coupled device camera (Hamamatsu Photonics, Hamamatsu City, 
Japan) was used for acquisition of fluorescent images.  Fluorescent-stained cells were 
observed with the appropriate excitation and emission, and the average fluorescent 
intensities (Integrated Optical Density or mean IOD) were quantified using ImagePro 
Plus imaging software (version 5.0, Media Cybernetics, Silver Spring, MD).    A 
minimum of three field pictures were taken per well and averaged.  Fluozin 3-AM 
(Molecular Probes), a fluorescent dye specific for the unassociated Zn2+, was used for 
labile zinc imaging.  These were analyzed at 494-nm excitation and 516-nm emission.  
MTF-1-GFP nuclear translocation studies measured fluorescence at a 393-nm excitation 
and 509-nm emission.   
69
eNOS Promoter Luciferase Activity Assay 
1.6kb eNOS promoter constructs were generated by polymerase chain reaction 
(PCR) using human genomic DNA as a template.  The reverse primer common to all 
constructs binds immediately upstream of the ATG initiation codon of eNOS (5’ –
GTTACTGTG CGT CCA CTCTGCTGCC). The forward primer was 5’ – 
TGTAGTTTCCCTAGTCCCCC (840bp fragment).  A 3-bp mutation was introduced into 
the metal response element sequence within the 840bp construct.  The sequence -902 at -
890 in the human eNOS promoter was changed to GCAattACTCTGG by site-directed 
mutagenesis.
BAECs were then grown to 70% confluence and transfected for 24hrs with 0.4µg 
-gal (transfection efficiency control) and 1.6µg eNOS promoter-luciferase construct 
using an Effectene transfection kit (Qiagen, Velencia, CA).  Cells were then treated for 
an additional 18hrs with various doses of spermine NONOate (0-100µM) or H2O2 (0-
50µM).
 Plates were rinsed with DPBS and 200µL 1X Reporter Lysis Buffer (Promega, 
Madison, WI) was added to each well.  Plates were sealed with parafilm and frozen at -
80oC for 20min or until subsequent analysis.  Next, plates were put at 37oC for 30min. 
then vortexed for 30s and the cell solution transferred to a new eppendorf tube.  This tube 
was vortexed for an additional 15s and then centrifuged at 12,000g for 10min at room 
temperature.  The supernatant was then transferred to a new tube and placed on ice until 
analyzed. 
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 To normalize for transfection efficiency, -gal activity was measured.  In a 96-
well plate, 5-10µL cell lysate was combined with 40-45µL 1X Reporter Lysis Buffer and 
50µL -gal substrate (Qiagen, Velencia, CA) in 100µL total volume.  The plate was then 
allowed to incubate at 37oC for 30min.  Spectrophotometric readings were taken on a 
Thermo Electron Multiscan plate reader at 405nm throughout the 30min incubation 
period.
 Luciferase activities were measured luminometrically using a Thermo Electron 
Fluoroscan plate reader set as a luminometer.  Twenty microliters of cell lysate was 
combined with 100µL luciferase substrate (Qiagen, Velencia, CA) and a reading on the 
luminometer was taken immediately.   
mRNA Extraction and Quantitation 
 eNOS mRNA levels were analyzed in BAECs following 18hr spermine NONOate 
or H2O2 treatment.  Cells were grown in 6-well plates to confluence and treated in 10% 
fetal bovine serum containing medium for 18hr with various doses of spermine 
NONOate, H2O2, or a vehicle control.  Following treatment, RNA was isolated using the 
RNeasy Kit (Qiagen, Valencia, CA).  Final collection of RNA was in 40µL RNase free 
water.  Throughout the isolation process, RNA was kept on ice to ensure minimal 
degradation.  RNA concentrations were determined using 260 and 280nm readings from 
a Shimadzu spectrophotometer.   
 Next, cDNA was made from the RNA by following the Quantitect Reverse 
Transcriptase kit instructions (Qiagen, Valencia, CA).  QuantiTect SYBR Green PCR kit 
(Qiagen, Valencia, CA) was used for PCR master mix.  ROX (Invitrogen, Carlsbad, CA) 
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was used as a reference dye to normalize the fluorescent reporter signal from SYBR 
Green in the RT-PCR.  18S RNA was used to standardize sample concentration 
differences.  A Multiplex Quantitative PCR System Mx4000 was used for the Real Time 
PCR.
        
Protein Extraction 
BAECs were grown in 6-well plates to confluence and treated in regular serum 
media for 18hrs with various doses of spermine NONOate, H2O2, or a vehicle control.  
Following treatment, total protein was harvested.  Briefly, cells were rinsed with DPBS 
(MediaTech) and RIPA lysis buffer added to each well.  Cell were then collected and 
sheared with a 25-gauge needle 3X.  Lastly, samples were spun at 14,000Xg for 10min 
and the supernatant was collected.  Total protein concentrations were analyzed using Bio-
Rad protein assay (Bio-Rad, Hercules, CA) and Bovine Serum Albumin (BSA) for the 
protein standard curve.
Western Blotting 
Western Blot analysis was performed as previously described [25].  Total protein 
extracts (~20µg) were resuspended in 5X Laemmli protein sample buffer and boiled for 
5min.  Total protein was then separated on a 4-20% Tris-SDS-HEPES polyacrylamide 
gel (Gradiopore, Frenchs Forest, Australia) and electrophoretically wet-transferred to a 
Hybond-PVDF membrane (Amersham, Arlington Hts., IL).  The membranes were 
blocked with 5% nonfat dry milk in Tris buffered saline containing 0.1% Tween-20 
(TBST) overnight at 40C.  After blocking, the membranes were incubated at room 
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temperature for 2 hrs with the primary antibody (1:1,000 for -eNOS, BD Biosciences), 
washed 3X with TBST, and incubated with a mouse anti-rabbit IgG-horseradish 
peroxidase conjugated secondary antibody (Pierce, Rockford, IL) for 1 hr.  After 
washing, immunolabeled protein bands were visualized using chemiluminescence 
(SuperSignal West Fempto Substrate Kit, Pierce) on a Kodak Image Station 440CF with 
Kodak 1D Molecular Imaging Software.  Blots were stripped (Pierce Stripping Solution) 
and reprobed with -actin (1:1000, Sigma) to normalize for loading. 
Generation of MT-1 Adenoviral Expression Construct 
An adenoviral vector expressing MT-1 was constructed using the pAd/pENTR 
System (Invitrogen).  Briefly, a pAd/CMV plasmid containing an MT-1 cDNA (cDNA 
purchased from ATCC, Manassas, VA) was created and transfected into 293A cells.  A 
selected clone was propagated and viral lysates were collected and tittered per the 
manufacturer’s protocol.  The titer for the AdV.MT-1 preparation was 3.4x1010 plaque-
forming units per mL.  Infections on BAECs were performed for 120min with virus 
diluted in normal DMEM to the desired multiplicity of infection.  Verification of 
expression was performed using Western Blot analysis as described above using 20µg of 
protein extracts.
Quantification of Intracellular Zn2+ Levels 
 BAECs were grown on glass cover slips in 6-well plates and treated with various 
doses of spermine NONOate, H2O2, or a vehicle control in SFPRF media for 1hr at 370C.
After 30min of treatment, cells were loaded with 2.5µM Fluozin 3-AM (Molecular 
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Probes), a fluorescent dye specific for labile Zn2+.  Following the treatment period, cells 
were washed twice with SFPRF media and incubated for an additional 30min in the dark 
at 37oC (in the incubator).  Cell-coated glass cover slips were removed from the 6-well 
plate one at a time and put onto a glass slides.  These slides were analyzed by fluorescent 
microscopy as described above.    
MTF-1-GFP Nuclear Translocation 
 An MTF-1 construct was cloned (Sal I and Xma I) upstream of a GFP construct 
(Xma I and Not I) into the pEntr1A gateway vector system (Invitrogen).  Enzymatic 
digests were utilized to verify cloning products and their orientation.
BAECs were grown on glass cover slips in 6-well plates to 50-60% confluence, 
and were transduced with Lac Z (viral control) or MT-1 adenovirus at a multiplicity of 
infection (MOI) equal to 1000 for 24hrs.  Then, they were transfected with the MTF-1-
GFP construct using Effectene transfection reagent (Qiagen, Valencia, CA).  MTF-1-GFP 
translocation was determined using fluorescent microscopy as described above.  A higher 
mean IOD correlated to more nuclear localization.  A minimum of 3 field pictures were 
taken per well and averaged.  The mean ± standard deviation was calculated and a P<0.05 
was considered statistically significant from the control.   
Nuclear Extract Preparation and EMSA 
BAECs were grown to 80% confluence and transduced with metallothionein 1 
(MT-1) or a GFP transduction control adenovirus at a MOI equal to 1000.  Twenty four 
hours post transduction, cells were treated for 18hr with 5µM H2O2 or 25µL spermine 
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NONOate.  Following treatment, nuclear extracts were prepared using the NE-PER 
nuclear extraction kit (Pierce).  Electrophoretic mobility shift assays (EMSA) were 
performed using biotinylated double stranded oligonucleotide corresponding to MRE site 
at -898 of eNOS promoter.  We also utilized an MRE mutant oligonucleotide where 3 
nucleotides at -898 were mutated from TGC to ATT in the human eNOS promoter.  The 
single stranded oligonucleotides were biotinylated using Biotin 3´ End DNA Labeling Kit 
(Pierce) to incorporate 1-3 biotinylated ribonucleotides (Biotin-11-UTP) onto the 3´ end 
of DNA strands using terminal deoxynucleotidyl transferase (TdT) and then annealed to 
make it double stranded.  Binding reactions involved incubating 7.5 g of nuclear extract 
with biotinylated oligonucleotide and 1 g poly(dI.dC) for 20min at room temperature. 
The DNA-protein complexes were resolved on a 5% nondenaturing polyacrylamide gel 
in 1X TBE buffer, then transferred to nylon membrane and biotinylated oligonucleotide 
was detected using a LightShift® Chemiluminescent EMSA kit (Pierce) and visualized 
on a Kodak Image station 440 CF (Eastman Kodak). 
Statistical Analysis
Values are expressed as the means ± standard error of the mean from at least three 
experiments.  Statistical analysis between experimental groups was performed by one 
way ANOVA or T-test using the Graph Pad Prism 4.0 statistical analysis software 
program.  The P < 0.05 was considered statistically significant. 
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RESULTS 
Initial experiments determined cellular toxicity in bovine aortic endothelial cells 
(BAECs) to 18hr exposures of various doses of the nitric oxide (NO) donor spermine 
NONOate or hydrogen peroxide (H2O2) using lactate dehydrogenase release (LDH).
LDH release was measured in the media of treated cells and normalized to Triton-X 100 
lysed cells (100% cell death). No significant toxicity exists in BAECs following an 18hr 
H2O2 treatment at doses of 25µM and less (Figure 1), while doses of spermine NONOate 
at 100µM and less were not found to be toxic (Figure 2).   
We next determined whether non-toxic doses of spermine NONOate and H2O2
would cause increases in cellular free zinc levels.  Cells were grown on glass cover slips 
to minimize auto-fluorescence from the plastic and the zinc fluorophore, Fluozin-3 AM, 
was used to measure cellular labile zinc levels.  Doses of 5µM H2O2 up to 50µM 
increased cellular free zinc 1.5-9.5 fold (Figure 2, P<0.05).  Doses of 25µM spermine 
NONOate up to 100µM increased cellular free zinc at least 2-fold (Figure 4, P<0.05).
Knowing that H2O2 and NO can be detrimental at higher doses to eNOS, we next 
looked at the effect of the lowest doses of H2O2 and spermine NONOate that still 
significantly increased labile zinc levels on eNOS mRNA levels utilizing real time PCR.  
Cells were treated for 18hrs with 25µM spermine NONOate or 5µM H2O2 and then RNA 
was isolated using a Qiagen RNeasy kit. cDNA was made using the Qiagen QuantiTect 
Reverse Transcriptase kit and QuantiTect SYBR Green PCR kit was used for the master 
mix.  18s RNA was used to normalize cDNA loading.  Results indicated that 18hr 
treatment with 5µM H2O2 increased eNOS mRNA (Figure 5), and that 18hr treatment 
with 25µM spermine NONOate increased eNOS mRNA (Figure 6).     
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 Then, we followed up the mRNA experiments and looked at the effect of these 
treatments on total eNOS protein levels.  Cells were grown to confluence, treated for 
18hrs with 5µM H2O2 or 25µM spermine NONOate, and protein was harvested.  Western 
Blot analysis indicated that total eNOS significantly increased with both treatments 
(Figure 7 and Figure 8 respectively).
Our initial analysis of the eNOS promoter indicated the presence of a putative 
heavy metal response element (HRE) located at -899/-893 in the 5’-flanking region of the 
human eNOS gene sequence.  We wanted to determine whether increases in eNOS 
mRNA and protein levels following H2O2 or spermine NONOate treatments were due to 
eNOS transcriptional alterations through the eNOS MRE.  This was done by using an 
eNOS promoter-luciferase activity assay with a wild type or MRE-mutant 1.6kb human 
eNOS promoter-luciferase construct.  Using metallothionein (MT-1) adenovirus, we 
investigated whether alterations that may be found in eNOS promoter luciferase activity 
were due to increases in cellular free zinc.  Cells were grown to 70% confluence and 
virally transduced with MT-1 adenovirus or a GFP viral control.   Six to eight hours later, 
they were dually transfected with a -gal transfection efficiency control construct and a 
WT or mutant eNOS promoter luciferase construct.  After 24h, cells were treated with 
5µM H2O2 or 25µM spermine NONOate for 18h.  Lastly, they were harvested for eNOS 
promoter luciferase and -gal activity assays.  Our data indicate that 5µM H2O2 (Figure 
9) and 25µM spermine NONOate (Figure 9) significantly increased eNOS promoter 
luciferase activity.  MT-1 overexpression decreased basal eNOS promoter luciferase 
activity and abolished spermine NONOate and H2O2 stimulated eNOS promoter 
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luciferase activity (Figure 9).  The MRE-mutated eNOS promoter luciferase construct 
resulted in decreased eNOS promoter luciferase activity in all samples (Figure 9).   
   We developed a MTF-1-GFP construct that can be transfected into cells to 
observe MTF-1 nuclear localization.  Since MTF-1 is known to work directly with MT-1 
and to be activated by alterations in labile zinc levels, we determined whether the MT-1 
transduction decreased MTF-1 nuclear translocation.  Cells were grown to 70% 
confluence on glass cover slips and transduced with MT-1 or a GFP viral control for 24h.  
Then, they were transfected with the MTF-1-GFP construct.  Twenty four hours post 
transfection, fluorescence microscopy was used to quantitate nuclear translocation of 
MTF-1-GFP.  MT-1 overexpression decreased MTF-1-GFP nuclear translocation (Figure 
10).
 Lastly, we wanted to determine whether our 18hr spermine NONOate and H2O2
treatments were causing zinc dependent activation of MTF-1 binding to the eNOS 
promoter.  Therefore, we used MTF-1 bandshift analysis and MT-1 viral transduction.
Cells were grown to 80% confluence and virally transduced with either a GFP control or 
MT-1 adenovirus.  Twenty four hours post transduction; cells were treated for 18hrs with 
spermine NONOate or H2O2.  Following treatment, nuclear extracts were prepared and 
MTF-1 bandshift analysis was carried out.  Results indicated that both treatments lead to 
increased MTF-1 binding to the eNOS MRE and that these increases are abolished with 
MT-1 overexpression.
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DISCUSSION 
Persistent pulmonary hypertension of the newborn (PPHN) is associated with 
endothelial dysfunction, and endothelial cells have been shown to increase their 
generation of hydrogen peroxide and superoxide both from the “uncoupling” of 
endothelial nitric oxide synthase (eNOS) and from the activation of nicotinamide adenine 
dinucleotide phosphate-oxidase (NADPH) complex.  Both eNOS mRNA and protein 
levels are decreased in PPHN, contributing to decreased levels of NO production.   In the 
present study, we examined the effect of physiologic levels of spermine NONOate and 
hydrogen peroxide (H2O2) in bovine aortic endothelial cells (BAECs) on the eNOS 
expression.  Under normal in vivo conditions, endothelial cells are continually exposed to 
low amounts of nitric oxide (NO) and H2O2.  Findings from this study demonstrate a 
pathway of eNOS activation in BAECs by low dose treatments of the NO donor, 
spermine NONOate, and of H2O2 through free zinc release and heavy metal responsive 
transcription factor 1 (MTF-1) activation.  Specifically, this study found that these 
exposures increased BAEC: (1) eNOS promoter activity, (2) eNOS mRNA, (3) total 
eNOS protein, (4) labile zinc, and (5) MTF-1 binding to eNOS promoter MRE.  These 
results provide evidence of MTF-1 and zinc in the regulation of eNOS.
The mechanism by which NO regulates eNOS activity and gene expression is 
incompletely understood.  In the vasculature, the free radical NO is produced mostly by 
the endothelial NOS isoforms, with a minor contribution from neuronal-type NOS in 
smooth muscle cells [7].  It can diffuse rapidly from the endothelium to adjacent cells, 
where it is important in maintaining vascular homeostasis through vasodilation by 
activation of soluble guanylate cyclase, production of cGMP, and ultimately, activation 
79
of a variety of downstream effectors, including cGMP-dependent protein kinase, cGMP-
modulated ion channels, and phosphodiesterases [27].  NO is also very important for 
preventing platelet aggregation and leukocyte adhesion, and lowering vascular smooth 
muscle proliferation.  Many of the functions of endothelial –derived NO seem to prevent 
or inhibit atherosclerosis [8].  Its production is regulated by changes in eNOS enzyme 
activity and/or eNOS gene expression.  Our toxicity results with the NO donor, spermine 
NONOate, in BAECs indicated no significant toxicity as measured by lactate 
dehydrogenase (LDH) release with an 18hr treatment and doses up to 100µM.    
The mechanisms by which H2O2 regulates eNOS are complex and incompletely 
understood.  Studies done by Drummond, et. al. have found concentration- and time-
dependent increases in eNOS mRNA and protein induced by H2O2 through increases in 
transcription and mRNA stability [10].  Their studies utilized doses of 100 and 150µM 
H2O2 in BAECs for 24h exposures, while our studies found significant toxicity in BAECs 
at 50µM H2O2 for an 18h exposure (Figure 2).  This contradiction could be due to cell 
passage or inter-animal differences.  Our study utilized cells less than passage 10 and 
from the same animal.  Despite varying doses and treatment times, results from our study 
had similar conclusions that H2O2 can increase eNOS mRNA and total protein.
Metallothioneins (MT) are small, cysteine-rich proteins that avidly bind to metals 
such as zinc, copper, and cadmium to reduce their concentration to a physiological or 
non-toxic level [15].  The concentration of exchangeable zinc in a cell is regulated by the 
sulfhydryl –rich MT, which is found in most organisms and tissues [28, 29].  In addition 
to regulating zinc, MT itself is involved in protecting against oxidative stress by virtue of 
its remarkably high content of cysteinyl residues [28, 30, 31].
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Past studies have established that oxidizing compounds can cause release of zinc 
from proteins, such as MT, through oxidation of zinc-thiolate bonds [32, 33].  Both NO 
and H2O2 are compounds capable of oxidizing zinc-thiolate bonds and releasing free zinc.
Interestingly, we found low, nontoxic doses of H2O2 and spermine NONOate for 1hr in 
BAECs to significantly increase intracellular labile zinc levels, 1.9-2.0-fold, as measured 
by the zinc fluorophore, Fluozin-3AM.               
Zinc can have either positive or negative effects on cellular physiology depending 
on the local concentration, localization, and/or state [34].  Excess amounts of free zinc 
can be detrimental and exacerbate cellular damage both in vivo and in vitro [35-37].
However, at certain levels, zinc appears to protect against DNA damage and apoptosis 
caused by oxidative stress [38].  Zinc is very tightly regulated since it serves many 
essential cellular roles [39, 40].  Several hundred enzymes are known to require zinc for 
proper functioning and well over a thousand transcription factors contain zinc-binding 
sequences [41-43].  In fact, the zinc finger protein structure is the most prevalent DNA 
binding motif of transcription factors [44].  In a number of cell lines, zinc inhibits 
apoptosis and its depletion induces characteristic apoptotic death [45, 46].
Results from this study in BAECs found immediate increases in labile zinc 
following spermine NONOate or H2O2, followed by increased eNOS mRNA (1.6-2.9-
fold), total protein (1.3-1.9-fold), and promoter activity (1.7-2.9-fold).  This agrees with 
previous data from our lab that found an 18hr 6µM H2O2 treatment in BAECs 
significantly increased total eNOS protein levels [13].  Increases in eNOS promoter-
luciferase activity with spermine NONOate and H2O2 treatment were zinc-dependent, 
since they were abolished with MT-1 viral transduction.  MT-1 transduction also 
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decreased eNOS promoter-luciferase activity in untreated BAECs, suggesting that zinc is 
at least partially involved in basal eNOS promoter activity (Figure 11).  We also looked 
at eNOS promoter luciferase activity with a mutated MRE in the eNOS promoter 
construct.  Our results indicated that the MRE mutant lowered basal eNOS promoter 
activity as well as H2O2 and spermine NONOate induced eNOS promoter activity.  MT-1 
transduction also significantly decreased spermine NONOate and H2O2 treated levels of 
eNOS promoter luciferase activity.
Treatment with NO or H2O2 could induce zinc-activated transcription of genes 
encoding antioxidant proteins. One of the most obvious proteins involved would be MT 
since MT expression is induced by zinc and it is a potent antioxidant [28-30, 47, 48].
MTF-1 plays a central role in the transcriptional activation of the MT gene in response to 
heavy metals and oxidative stress [15, 49].  In our MTF-1 bandshift analysis, we found 
that low dose, 18h spermine NONOate and H2O2 treatments in BAECs both increased 
MTF-1 bound to the eNOS MRE.  The H2O2 data agrees with recent data from Zhang, et. 
al., which found that in a cell free system, MTF-1 could be activated indirectly by H2O2
through release of zinc from oxidized MT [15].
 It is also becoming increasingly apparent that phosphorylation by multiple 
kinases including protein kinase C (PKC), c-Jun N-terminal kinase (JNK) and tyrosine 
kinase, is involved in the metal-dependent transactivation of MTF-1 [50-52].  However, 
further studies will need to be carried out to examine the involvement of these various 
kinases in MTF-1 transcriptional activation following low dose spermine NONOate and 
H2O2.
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In conclusion, low dose NO and H2O2 both appear to activate eNOS in a zinc 
dependent manner by liberating cellular stores of zinc and activating MTF-1, which then 
binds to the eNOS promoter metal response element.  Further studies will need to be done 
to look at the involvement of other zinc finger transcription factors, such as Sp-1.  Studies 
here utilized an 18hr, low dose NO and H2O2 treatment and therefore did not mimic a 
disease state, such as PPHN, where there is a chronic, high production of oxidative 
species.  However, an understanding of eNOS regulation may help to identify new 
pathways and novel therapies for diseases such as PPHN.
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FIGURE LEGENDS 
Fig. 1.  18hr treatment of BAECs with H2O2 leads to significant LDH release at doses of 
50µM and higher.  BAECs were grown to confluence and treated for 18hr with H2O2 in 
regular media.  Media was harvested and LDH release was measured using a Rosche 
LDH colorometric assay kit and reading at 492nm on a Multiscan platereader. All values 
are mean ± SEM (n=6). * P<0.05 vs. 0µM sample. 
Fig. 2.  18hr treatment of BAECs with Spermine NONOate does not lead to significant 
LDH release at doses of 100µM and less.  BAECs were grown to confluence and treated 
for 18hr with spermine NONOate in regular media.  Media was harvested and LDH 
release was measured using a Rosche LDH colorometric assay kit and reading at 492nm 
on a Multiscan platereader. All values are mean ± SEM (n=12). * P<0.05 vs. 0µM 
sample. 
Fig. 3.  A 1hr treatment with H2O2 leads to increases in cellular level of free zinc.  
BAECs were exposed to H2O2 for 1hr in SFPRF media.  Cells were rinsed and then 
loaded with 1µM Fluozin-3.  An Olympus scope and GFP cube were used to take 
pictures and Image Pro Software to quantitate fluorescence.  Results found that 5µM 
H2O2 were sufficient to increase cellular free zinc levels.All values are mean ± SD (n=6).
* P<0.05 vs. 0µM H2O2.
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Fig. 4.  A 1hr treatment with Spermine NONOate leads to increases in cellular level of 
free zinc.  BAECs were exposed to Spermine NONOate for 1hr in SFPRF media.  Cells 
were rinsed and then loaded with 1µM Fluozin-3.  An Olympus scope with a GFP cube 
was used to take pictures and Image Pro Software to quantitate fluorescence.  Results 
found that 25, 50, and 100µM Spermine NONOate were sufficient to increase cellular 
free zinc levels.  All values are mean ± SD (n=6).  * P<0.05 vs. 0µM Spermine 
NONOate.
Fig. 5.  4hr H2O2 treatment of BAECs leads to significant increase in eNOS mRNA 
levels.  BAECs were treated for 4hrs with H2O2 in regular media.  mRNA was isolated 
from the cells and cDNAs were made.  Quantitative real time PCR and normalization to 
18s RNA was used to quantitate the levels of eNOS mRNA.  Results found that 5µM 
H2O2 is sufficient to significantly increase eNOS mRNA.  All values are mean ± SD 
(n=5).  * P<0.05 vs. 0µM H2O2.
Fig. 6.  4hr Spermine NONOate treatment of BAECs leads to significant increase in 
eNOS mRNA levels.  BAECs were treated for 4hrs with Spermine NONOate in regular 
media.  mRNA was isolated from the cells and cDNAs were made.  Quantitative real 
time PCR and normalization to 18s RNA was used to quantitate the levels of eNOS 
mRNA.  Results found that 25µM Spermine NONOate is sufficient to significantly 
increase eNOS mRNA.  All values are mean ± SD (n=5).  * P<0.05 vs. 0µM Spermine 
NONOate.
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Fig. 7.  A 4hr treatment with H2O2 leads to increases in total eNOS protein levels.  
BAECs were exposed to H2O2 for 4hrs in SFPRF media. Western Blot analysis indicated 
that total eNOS levels increased at some doses of H2O2.  All values are mean ± SD (n=5).  
* P<0.05 vs. 0µM H2O2.
Fig. 8.  A 4hr treatment with Spermine NONOate leads to increases in total eNOS protein 
levels.  BAECs were exposed to Spermine NONOate for 4hrs in SFPRF media. Western 
Blot analysis indicated that total eNOS levels increased at some doses of Spermine 
NONOate.  All values are mean ± SD (n=5).  * P<0.05 vs. 0µM Spermine NONOate. 
Fig. 9.  Increases in eNOS promoter luciferase activity due to spermine NONOate or 
H2O2 treatments are zinc dependent and acting through the eNOS MRE.  The 
overexpression of MT-1 decreases eNOS promoter luciferase activity in untreated, 
Spermine NONOate, and H2O2 treated samples.  However, in the mutant, the 
overexpression of MT-1 also decreases eNOS promoter luciferase activity.  BAECs were 
transduced with MT-1.  24hrs later, the BAECs were co-transfected with either WT or 
mutant eNOS promoter luciferase and -gal.  24hrs later, cells were harvested and -gal 
and luciferase activities were measured by adding their respective substrates and reading 
on a plate reader or luminometer.  All values are mean ± SEM (n=3). * P<0.05 vs. GFP 
WT. 
Fig. 10.  Overexpression of MT-1 in BAECs leads to a decrease in MTF-1 nuclear 
localization.  BAECs were transduced with Lac Z or MT-1 adenovirus at MOI=1000.
91
24hrs later, they were transfected with MTF-1 GFP.  24hrs more, an Olympus scope and 
GFP cube were used to take pictures of MTF-1-GFP localization and Image Pro software 
was used to quantitate nuclear brightness.  All values are mean ± SEM (n=5). * P<0.05
vs. Lac Z transduction. 
Fig. 11. Overexpression of MT-1 attenuates NO and H2O2 induced increases in MTF-1 
bandshift levels.  BAECs were grown to ~80% confluency and transduced with GFP or 
MT-1 adenovirus at MOI=1000.  24hrs later, cells were treated for 18hr with Spermine 
NONOate or H2O2.  Nuclear protein extracts were made and bandshift analysis was 
performed. All values are mean ± SEM (n=6). * P<0.05 vs. GFP UTD. 
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ABSTRACT 
A change in endothelial function is thought to play an important role in the 
development of pulmonary hypertension.  We have previously demonstrated, in ovine 
models of pulmonary endothelial dysfunction, that there are changes in the synthesis and 
the activity of nitric oxide (NO).  Hypertensive vasoconstriction is postulated to involve 
the degradation of NO by reactive oxygen species (ROS), especially the superoxide 
anion.  The release of superoxide may be increased in the dysfunctional vascular 
endothelium.  Antioxidant therapy has been proposed as a treatment regimen for 
pulmonary hypertension and other pathologies linked to endothelial dysfunction.  Since 
the critical mediator of pulmonary vasorelaxation is generation of NO by the endothelial 
NOS (eNOS) protein we undertook a series of studies to determine the effects of pro-and 
anti-oxidants on eNOS function in ovine pulmonary arterial endothelial cells (PAECs).  
In initial studies we evaluated the effect of elevating superoxide levels in ovine PAECs 
by treating cells with the CuZnSOD inhibitor, diethyldithiocarbamate (DETC).  
Superoxide levels in cells were quantitated using fluorescent microscopy and the 
superoxide sensitive dye, dihydroethidium.  After 4h of exposure, superoxide levels were 
elevated by 2.1-fold compared to untreated cells (P < 0.05).  When eNOS activity was 
determined in DETC-treated cells, a 38% reduction in activity was detected compared to 
untreated cells (P < 0.05).  Western Blot analysis revealed that eNOS protein levels were 
also decreased by 34.7% (P < 0.05).  To investigate the mechanism for this decrease 
recombinant eNOS protein was exposed to a xanthine/xanthine oxidase superoxide 
generating system.  Analysis of the eNOS protein indicated that superoxide induced 
fragmentation of the eNOS protein.  Thus, we suggest that the activity of the eNOS 
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enzyme is sensitive to the cellular redox environment and that the increases in superoxide 
production thought to be associated with endothelial cell dysfunction result in the 
inhibition of the eNOS enzyme by inducing enzyme fragmentation.  
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INTRODUCTION
Published evidence suggests that normal pulmonary vascular reactivity and 
vascular smooth muscle cell proliferation is regulated by a complex interaction of 
vasoactive substances produced by the endothelium [1-3].  The development of 
hypertensive states in both the pulmonary and systemic circulatory systems is associated 
with increased vascular reactivity and the disruption of these regulatory mechanisms [4-
9].  In most animal models of hypertension, there is impaired endothelium-dependent 
vaso-relaxation to agonists such as acetylcholine [10, 11], however, endothelial 
dysfunction has different characteristics depending on the model utilized [10].   
Endothelial dysfunction may be defined as an imbalance between the synthesis, release or 
effect of endothelial factors capable of relaxing vascular smooth muscle or 
vasoconstrictor substances that can counteract these effects.  This imbalance manifests 
itself as a reduction in endothelium-dependent vasodilatory response, or as an increased 
vasoconstrictor response [12].  Other functions of the endothelium may also be affected, 
such as the adhesion of platelets and leukocytes with the vascular wall and increased 
growth and migration of smooth muscle cells [12].   
Nitric Oxide (NO) is an endothelium-derived relaxing factor synthesized by the 
oxidation of the guanidino nitrogen moiety of L-arginine following activation of nitric 
oxide synthase (NOS) [13].  After certain stimuli, such as shear stress and the receptor 
binding of specific vasodilators (endothelium-dependent vasodilators), NO is synthesized 
and released from the endothelial cell by the activation of endothelial NOS (eNOS) [14, 
15].  Once released from endothelial cells, NO diffuses into vascular smooth muscle cells 
and activates soluble guanylate cyclase (sGC), a heterodimer with 1 and 1 subunits 
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which catalyzes production of guanosine-3',5'-cyclic monophosphate (cGMP) from 
guanosine-5'-triphosphate.  cGMP induces vascular smooth muscle relaxation through 
activation of a cGMP-dependent protein kinase [16].  Endothelium-derived NO (and the 
resulting cGMP) is an important mediator of vascular tone and an inhibitor of platelet 
aggregation and smooth muscle mitogenesis [10, 17].  
During the last several years it has become clear that oxidative inactivation of NO 
is likely to be important in the development of several pathologic conditions including 
atherosclerosis, hypercholesterolemia, hypertension, and diabetes [12].  Studies have 
shown that in the blood vessel, the balance existing between the steady state levels of NO 
and the superoxide anion appears to be disrupted resulting in a decrease in the bio-
availability of NO [10, 12].  For example, large amounts of nitrogen oxides are released 
from vessels in an oxidatively degraded state in cholesterol-fed rabbits [18].  Treatment 
these rabbits with PEG-superoxide dismutase (SOD) dramatically increased endothelium-
dependent vascular relaxation, suggesting a role for superoxide in oxidative inactivation 
of NO [19].  There is evidence that reactive oxygen species also diminish NO bioactivity 
in humans.  For example, infusion of ascorbic acid improves vascular responses to 
acetylcholine in cigarette smokers [20].  In the endothelium, cycloxygenase [21], 
xanthine oxidase [22], and NADPH oxidase [23] have been identified as significant 
producers of superoxide.  More recent studies have indicated that NOS itself may also be 
a significant producer of superoxide during the development of nitrate tolerance [8].  
Interestingly, the use of protein kinase C inhibitors was shown to decrease the production 
of superoxide in the tolerant vessels, suggesting that phosphorylation of eNOS by PKC 
may play a role in eNOS superoxide production [8].  NOS also produces superoxide 
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when the bioavailability of tetrahydrobiopterin or L-arginine are low [24].  Both 
superoxide and NO are free radicals (i.e., they contain an unpaired electron in their outer 
orbital). When exposed to each other, they undergo a facile radical-radical reaction that 
proceeds at a rate recently estimated to be 7 x 109 mol-1.L.s-1 [25, 26]. This is 
approximately three times faster than the reaction rate for superoxide with either the Mn- 
or CuZn SOD.  Thus, in a compartment in which both NO and SOD exist, there may be a 
propensity for superoxide to preferentially react with NO rather than SOD, depending on 
the relative concentrations of NO and SOD present. 
It is unclear whether ROS can directly inhibit the eNOS enzyme or whether they 
exert their effects indirectly by scavenging the NO produced by the eNOS protein. Thus, 
the present study was undertaken to determine whether modulations in the cellular redox 
state in ovine PAECs would alter either the expression or activity of eNOS.  The results 
obtained indicated that increasing superoxide levels (a pro-oxidant environment) 
decreased eNOS activity and protein levels.
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MATERIALS AND METHODS  
Cell Culture 
Primary cultures of ovine pulmonary arterial endothelial cells (PAECs) were 
isolated as detailed previously [27].  Endothelial cell identity was confirmed by their 
typical cobblestone appearance, contact inhibition, specific uptake of 1,1’-dioctadecyl-
1,3,3’,3’-tetramethyllindocarbocyanine perchlorate-labeled acetylated low-density 
lipoprotein (Molecular Probes, Eugene, OR), and positive staining for von Willebrand 
factor (Dako, Carpentaria, CA).  PAECs were grown in Eagle DMEM containing 1g/l 
glucose and phenol red (MediaTech, Herndon, VA), supplemented with 10% fetal bovine 
serum (Hyclone, Logan, UT), antibiotic-antimycotic (MediaTech), basic fibroblast 
growth factor (bFGF 10ng/mL) (Sigma-Aldrich, St. Louis, MO).  Cells were incubated in 
21% O2 and 5% CO2 at 37oC.  Cells were used at passage less than 10.
Analysis of Cellular Superoxide Generation
To determine the effect of DETC on cellular superoxide levels in PAECs, ovine 
PAECs were grown overnight in serum free DME-H16 with 1g/L glucose.  Cultured 
PAECs were treated for 4h with DETC (1mM) or a vehicle control.  PAECs were then 
loaded with the superoxide sensitive dye dihydroethidium (10µM) (Sigma-Aldrich, St. 
Louis, MO), for a further 15min, washed with PBS, and imaged live using a Nikon 
TE300 inverted fluorescent microscope.  Dihydroethidium-stained cells were observed 
using excitation at 518nm and emission at 605nm.  Fluorescent images were captured 
using a Nikon Cool-Snap digital camera and quantified using Metamorph software 
(Fryer) under identical imaging conditions.  Statistical analyses between treatment groups 
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were carried out as detailed below.  Specificity of dihydroethidium to detect superoxide 
was demonstrated by pre-incubating cells with PEG-SOD (50units) prior to the addition 
of DETC.  Six separate experiments were performed and combined for the data in this 
experiment.   
Assay for NOS Activity
NOS activity was determined by two methods: the Busch assay and NOx probe 
(Apollo 4000 Free Radical Analyzer, World Precision Instruments, Inc.).  Cultured 
PAECs were treated for 4h with DETC (1mM) or a vehicle control and then, NOS 
activity was measured.  The first method, the Busch assay, measures the formation of 3H-
citrulline from 3H-arginine as we have previously described [28-30].  Briefly, subcellular 
fractions (100µg) were incubated at 37oC for 45min in the presence of 1 mM NADPH, 
14µM tetrahydrobiopterin, 5µM FAD, 1mM MgCl2, 10µM unlabeled L-arginine, 0.1µCi 
[3H]-L-arginine, and in the presence or absence of other cofactors (calmodulin and 
calcium).  The reaction was stopped by the addition of 4oC stop buffer (20 mM sodium 
acetate, pH 5, 1 mM L-citrulline, 2 mM EDTA, and 0.2 mM EGTA).  Samples were 
applied to columns containing 1 ml of Dowex AG50W-X8 resin, Na+ form, pre-
equilibrated with 1N NaOH.  [3H]-citrulline was then quantitated by scintillation 
counting.
The second method measured NOx production in the media with a NOx specific 
probe.  Briefly following treatment, media was collected and NOx levels were measured.  
Potassium Nitrate solutions, made in media, were used to make a standard curve for 
determining NOx levels. 
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Protein Extraction
Cultured PAECs were treated for 4h with DETC (1mM) or a vehicle control.  
Following treatment, cells were rinsed with DPBS (MediaTech) and RIPA lysis buffer 
added to each well.  Cell were then collected and sheared with a 25-gauge needle 3X.  
Lastly, samples were spun at 14,000Xg for 10min and the supernatant was collected.  
Protein concentrations were analyzed using Bio-Rad protein assay (Bio-Rad, Hercules, 
CA) and Bovine Serum Albumin (BSA) for the protein standard curve.
Western Blotting 
Western Blot analysis was performed as previously described [31].  Total protein 
extracts (~20µg) were resuspended in 5X Laemmli protein sample buffer and boiled for 
5min.  Total protein was then separated on a 4-20% Tris-SDS-HEPES polyacrylamide 
gel (Gradiopore, Frenchs Forest, Australia) and electrophoretically wet-transferred to a 
Hybond-PVDF membrane (Amersham, Arlington Hts., IL).  The membranes were 
blocked with 5% nonfat dry milk in Tris buffered saline containing 0.1% Tween-20 
(TBST) overnight at 40C.  After blocking, the membranes were incubated at room 
temperature for 2 hrs with the primary antibody (1:1,000 for -eNOS, BD Biosciences), 
washed 3X with TBST, and incubated with a mouse anti-rabbit IgG-horseradish 
peroxidase conjugated secondary antibody (Pierce, Rockford, IL) for 1 hr.  After 
washing, immunolabeled protein bands were visualized using chemiluminescence 
(SuperSignal West Fempto Substrate Kit, Pierce) on a Kodak Image Station 440CF with 
Kodak 1D Molecular Imaging Software and normalized to immunolabeled -actin 
(1:1000, Sigma) on the same blot.  To assure equal protein loading, duplicate 
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polyacrylamide gels were run, one normal and one stained with Coomassie blue. Four 
separate experiments were performed and combined for the data in this experiment.         
Expression and Purification of eNOS 
 The poly-His-pCWeNOS vector (source) was transformed into the E.coli strain BL21 
(DE3) plysS (source) for expression of recombinant human eNOS.  LB cultures of poly-
His-pCWeNOS, containing 100µg/ml of ampicillin, were grown until an OD600 of 0.8 
was reached.  These cultures were then used to inoculate 6 liters of LB (pre-chilled to 
<15˚C) split into four 2.8-litre Fernbach flasks.  Induction of the bacterial promoter, ???, 
was then carried out by the addition of IPTG to a final concentration of 2mM.  Cultures 
were then incubated at 18˚C for 18h with a rotation rate of 220rpm prior to harvest by 
centrifugation. 
Purification of recombinant human eNOS was carried out using Calmodulin-
Sepharose as we previously described for preparation of recombinant neuronal NOS [32].  
The only significant difference was that here, DTT was added to all purification buffers 
mentioned above at a concentration of 10µM.
To expose purified human recombinant eNOS (2µg) to superoxide, purified eNOS 
fractions (2µg) were exposed to both xanthine (0.5mM) (Sigma-Aldrich, St. Louis, MO) 
and xanthine oxidase (0.5 units) (Sigma-Aldrich, St. Louis, MO) for 20 min.  Protein was 
then subjected to SDS-PAGE and stained with Coomassie blue.  As a negative control, 
purified eNOS was also exposed to the NO donor, Spermine NONOate (50µM) (Cayman 
Chemical, Ann Arbor, MI) for 20min.  The control groups were exposed to a vehicle 
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control for 20min.  Four separate experiments were performed and combined for the data 
in this experiment.         
Statistical Analysis
Values are expressed as the means ± standard deviation from at least three 
experiments.  Statistical analysis between experimental groups was performed unpaired 
T-test using the GB-STAT statistical analysis software program.  A p< 0.05 was 
considered statistically significant. 
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RESULTS 
Initially, experiments tested whether treating ovine PAECs with DETC could 
increase cellular superoxide levels.  DETC-mediated increases in superoxide production 
by ovine PAECs were measured using dihydroethidium, a superoxide-sensitive 
fluorescent dye, and fluorescent microscopy (Figure 1).  Results obtained demonstrated 
that exposure of ovine PAECs to DETC (1mM) for 4hrs resulted in a 105-fold increase in 
superoxide production (Figure 1 B, p < 0.05 vs Untreated), which was blocked in cells 
pre-incubated with PEG-SOD, an external SOD source (Figure 1, p<0.05 vs DETC + 
PEG-SOD).
The next set of experiments determined whether the DETC-mediated increase in 
superoxide levels altered the activity of the eNOS enzyme in ovine PAECs.  Exposure of 
PAECs to DETC invitro resulted in a 38% reduction in 3H-arg to 3H-citrulline conversion 
(Figure 2, p< 0.05 vs untreated control cells). We then examined eNOS protein levels in 
DETC treated and untreated PAECs using quantitative Western Blot analysis.  The 
results obtained indicated that ENOS protein levels were also reduced, by 34.7% (Figure 
3, p< 0.05 vs untreated cells).
The PAEC culture data suggested that superoxide inactivated eNOS, but we were 
uncertain whether an immediate component was involved.  To determine whether 
superoxide directly inactivated eNOS, we exposed purified recombinant human ENOS to 
xanthine/xanthine oxidase (X/XO) superoxide generating system, or to the NO donor 
spermine NONOate.  The results obtained (Figure 4) indicated that in the presence of 
X/XO the expected 135kD eNOS band was not observed.  Rather two smaller fragments 
were now observed (marked as * in Figure 4).  This effect was seen to be specific to 
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superoxide as this fragmentation was not observed when eNOS was exposed to the NO 
donor, spermineNONOate (Figure 4).  Thus, the mechanism of ENOS inhibition induced 
by high levels of superoxide appears to be via an induction of ENOS fragmentation.   
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DISCUSSION 
Controversy continues to exist over the possible alteration of NO synthesis in both 
pulmonary and systemic hypertensive patients and in animal models of these disease 
states.  However, the development of hypertension is fundamentally linked with the 
reduction in NO signaling.  As a consequence of the mechanical deformation of 
endothelial cells, there may be an increase in the production of free radicals such as the 
superoxide anion in hypertensive patients [33-35].  Normally, the concentration of 
superoxide remains low in physiological situations because the superoxide dismutase 
(SOD) enzyme reacts with it.  However, increased  superoxide production is possible 
from several sources within the endothelium, including cyclooxygenase [36], xanthine 
oxidase [22], NADPH oxidase [23], or even NOS, under specific conditions [8]. 
Whatever their source, the superoxide radical determines the viability of NO, as it can 
oxidize and de-activate NO thereby forming peroxynitrite (ONOO-) [25, 26].  
Peroxynitrite is a strong oxidizing agent and can react with biological molecules, 
including protein and non-protein sulfhydryls, DNA, and membrane phospholipids [37].  
Peroxynitrite is capable of nitrating free or protein-associated tyrosines and other 
phenolics [38].  Thus, a decrease in bio-available NO by its reaction with other free 
radicals could trigger the development of hypertensive states.  In fact, in an ovine model 
of pulmonary hypertension we have found that pretreatment of vessels with membrane-
permeable SOD or catalase enhanced calcium-ionophore-induced relaxations in 
pulmonary arteries from hypertensive but not control lambs [39]. These data indicate that 
superoxide and/or peroxynitrite formation may be involved in the impaired endothelium-
dependent relaxations displayed in the hypertensive lambs.  This model for PPHN 
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remained unclear, however, as to whether the mechanism of action of increased ROS 
generation, specifically superoxide, is due to its ability to react with NO or whether it can 
also directly inhibit eNOS activity.  The latter would represent another mechanism to 
limit NO release.  The results here showed that by directly exposing ovine PAECs to the 
CuZn SOD inhibitor, DETC, increased cellular oxidant stress in these cells by increasing 
superoxide levels.  With DETC exposure, we found a significant decrease in the ability of 
eNOS to metabolize L-arginine within 4 hours of treatment.  These results show that not 
only can superoxide react with NO to form peroxynitrite, thereby limit NO 
bioavailability; but also can also decrease eNOS activity.   
However, the precise mode or mechanism of this inhibition was not clear.  Our 
results showed that eNOS protein levels were reduced in the presence of DETC.  Since 
the half-life of the eNOS protein is thought to be >24h, this suggested that perhaps 
superoxide has a direct effect on the protein itself.  Exposing purified eNOS protein to 
superoxide produced a degradation of the eNOS protein into 2 fragments (approximate 
masses 70 and 60kD respectively), revealing that the mechanism for superoxide 
inhibition on eNOS occurs by enzyme fragmentation.  It is still unclear whether 
superoxide levels can attain those needed to induce enzyme fragmentation in vivo since 
the short half-life, and high reactivity of superoxide would tend to limit the likelihood of 
eNOS and superoxide interacting.  However, it is noteworthy that progressive endothelial 
dysfunction associated with advanced hypertension can be associated with increased free 
radical levels and lowered NO production and/or eNOS levels [40-43].  Superoxide 
induced degradation of eNOS demonstrated here could potentially be involved.  It is also 
possible that because eNOS is a multi-enzyme complex with both oxidative and reductive 
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domains the superoxide anion may also interfere with electron transfer at the different 
active sites of the protein during the oxidation/reduction phase resulting in reduced 
enzymatic catalysis.  Further studies will be needed to characterize the inhibitory 
mechanisms of superoxide on eNOS. 
 In conclusion, our results indicate that the NO-NOS system represents a complex 
bioregulated pathway whose regulation is tightly associated with the redox status of the 
cell.  The high oxidant potential of NO suggests that its generation in a biological system 
must be tightly regulated.  As demonstrated in our studies increasing superoxide levels 
within the cell (analogous to producing a more oxidized environment) resulted in a 
significant reduction in the catalytic capability of eNOS.  Thus, the increases in ROS that 
may be involved in the development of endothelial dysfunction associated with a number 
of vascular diseases may cause a reduction in eNOS activity, possibly by inducing eNOS 
fragmentation, as well as increasing the destruction of NO by formation of other radicals.  
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FIGURE LEGENDS 
Figure 1. In situ detection of superoxide in ovine pulmonary arterial endothelial cells.
Panel A.  Representative fluorescent images of dihydroethydium (DHE)-treated ovine 
PAECs in response the CuZnSOD inhibitor DETC (1mM). Conversion of DHE by 
superoxide to ethidium results in red nuclear fluorescence.  Under identical imaging 
conditions more fluorescent cells were observed in the presence of DETC.  Pre-
incubation with PEG-SOD (50 units) reduced the ethidium signal, and indicates its 
specificity for superoxide. 
Panel B.  The fluorescent intensity of each image was quantified using Metamorph 
Imaging software and represented graphically.  N=6.  Values are mean ± SD.  * p< 0.05 
vs Untreated, † p<0.05 vs DETC + PEG-SOD. 
Figure 2.  Increased superoxide production inhibits eNOS activity in ovine pulmonary 
arterial endothelial cells.  Ovine PAECs were treated for 4h with DETC (1mM) to inhibit 
CuZn SOD activity. Cell extracts were then prepared and the NOS activity was 
determined using 3H-arginine to 3H-citrulline conversion.  Activities are presented as a 
percentage of untreated (no DETC exposure) cells.  The data represents the mean + s.d of 
4 separate experiments.  * p < 0.05 vs untreated. 
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Figure 3.  Increased superoxide production decreases eNOS protein levels in ovine 
pulmonary arterial endothelial cells.   
Panel A.  Protein extracts (25µg) from ovine PAECs, exposed or not to DETC (1mM) for 
4h, were separated on a 7.5% SDS-polyacrylamide gel, electrophoretically transferred to 
Hybond membranes, and analyzed using a specific antiserum raised against eNOS.  
Untreated controls received vehicle only. A representative Western blot is shown.
Panel B.  The densitometric values for eNOS protein from ovine PAECs exposed or not 
to DETC (1mM) for 4h.   eNOS Protein is decreased by 34.7% by DETC exposure.  
Values are mean ± standard deviation from 4 experiments.  * p< 0.05 vs untreated. 
Figure 4.  Superoxide induces the degradation of eNOS.  Purified human recombinant 
eNOS (2µg) was exposed for 20min to either:  vehicle control, the superoxide (SO) 
generating system xanthine (0.5mM) and xanthine oxidase (0.5 units), or spermine 
NONOate (NO 50µM).  In the presence of X/XO superoxide the eNOS protein is 
degraded into two fragments (marked by *).  The gel is representative of 3 separate 
experiments. 
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ABSTRACT 
Newborns that do not survive persistent pulmonary hypertension of the newborn 
(PPHN) exhibit both an increase in the thickness of the smooth muscle cell (SMC) layer 
within pulmonary arterioles and an extension of this muscle to non-muscular arterioles.  
Oxidant production, associated with increased SMC growth, plays an important role both 
in the normal function of the vascular system as well as the pathogenesis of vascular 
disease.  The production of nitric oxide (NO) in the vessel wall by the enzyme endothelial 
nitric oxide synthase (eNOS) is dependent on essential cofactors, including the most 
potent naturally occurring reducing agent, tetrahydrobiopterin (BH4).  Although BH4 is 
thought to maintain the eNOS dimer, the exact mechanism of this maintenance is 
unknown.  Utilizing NIH3T3 cells, a line with very low BH4 levels, and bovine aortic 
endothelial cells (BAECs) our study set out to test the hypothesis that BH4’s role in the 
regulation of eNOS is due to its high antioxidant potential.  Our results in NIH3T3 cells 
demonstrate that catalase transduction decreases ROS levels, specifically H2O2, and 
increases eNOS total protein, dimer/monomer protein ratio and eNOS activity.  In 
BAECs, the addition of BH4 or L-sepiapterin, the substrate for the synthesis of BH4,
decreased ROS levels and increased eNOS dimer levels and activity.  The addition of 
BH4 to NIH3T3 cells also decreased ROS production.  These results suggest that the 
association of BH4 with eNOS may regulate eNOS protein levels and activity due to its 
high antioxidant potential. 
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INTRODUCTION
In persistent pulmonary hypertension of the newborn (PPHN), childbirth does not 
result in the normal decrease in pulmonary vascular resistance and coincident increase in 
pulmonary blood flow.  PPHN affects 5 in 1000 births of term or near term infants each 
year.  Newborns that die of PPHN exhibit both an increase in the thickness of the smooth 
muscle cell layer within pulmonary arterioles and an extension of this muscle to non-
muscular arterioles [1].  The proliferation of smooth muscle cells has been strongly 
linked to the generation of reactive oxygen species (ROS), such as superoxide (O2-.) and 
hydrogen peroxide (H2O2) [2-4].
Every cell type in the vascular wall, including fibroblasts [5], endothelial cells [6, 
7], and smooth muscle cells [8], has been shown to produce and be regulated by ROS.  
This oxidant production plays an important role both in the normal function of the 
vascular system, as well as the pathogenesis of vascular disease.
The endothelium plays a major role in the modulation of vascular homeostasis.  
One key molecule produced by the endothelium is nitric oxide (NO), produced by the 
enzyme endothelial nitric oxide synthase (eNOS).  eNOS catalyzes the oxidation reaction 
of L-arginine and molecular oxygen to L-citrulline and NO [9].  The production of NO in 
the vessel wall is dependent on essential cofactors, including the most potent naturally 
occurring reducing agent tetrahydrobiopterin (BH4).
Biopterin metabolism is thought to be critical in the regulation of NOS activity.  
In the absence of sufficient levels of BH4, previous in vitro studies have found that eNOS 
becomes uncoupled, resulting in decreased  NO production and increased superoxide (O2-
.) and hydrogen peroxide (H2O2) production [10, 11]. 
135
In a recent study by Wang, et. al., rats were supplemented with fructose in their 
diet, that is known to produce oxidative stress in vivo, and the results showed that 
endothelium-dependent relaxations were impaired [12].  Although, supplementing the 
fructose-fed rats with BH4 in the water did not significantly increase the vascular content 
of BH4, it did partially restore endothelium-dependent vascular relaxations and restore 
eNOS protein within the rat aortas [12]. 
Utilizing NIH3T3 cells, a line with very low BH4 levels, and bovine aortic 
endothelial cells (BAECs), our study was designed to test the hypothesis that BH4’s role 
in the regulation of eNOS is dependent on its high antioxidant potential.  The 
experimental results supported the hypothesis showing that the association of BH4 with 
eNOS regulated eNOS protein levels and activity. 
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MATERIALS AND METHODS  
Cell culture 
Primary cultures of Bovine pulmonary arterial endothelial cells (BAECs) were 
generously donated by Dr. J. Douglas Coffin at the University of Montana.  Endothelial 
cell identity was confirmed by their typical cobblestone appearance, contact inhibition, 
specific uptake of 1,1’-dioctadecyl-1,3,3’,3’-tetramethyllindocarbocyanine perchlorate-
labeled acetylated low-density lipoprotein (Molecular Probes, Eugene, OR), and positive 
staining for von Willebrand factor (Dako, Carpentaria, CA).  BAECs were grown in 
Eagle DMEM containing 1g/l glucose and phenol red (MediaTech, Herndon, VA), 
supplemented with 10% fetal bovine serum (Hyclone, Logan, UT), and antibiotic-
antimycotic (MediaTech).  NIH3T3 cells were purchased from _____  (_____).  These 
cells were grown in Eagle DMEM containing 1g/l glucose and phenol red (MediaTech, 
Herndon, VA), supplemented with 10% fetal calf serum (Hyclone, Logan, UT), and 
antibiotic-antimycotic (MediaTech).   Prior to experimental treatment (unless otherwise 
noted) cells were trypsinized, counted with a hemacytometer and replated in a 6, 24-, or 
96-well plate (Costar, Corning, NY) at densities of approximately 104/cm2 and allowed to 
adhere for at least 18hrs.  Cells were incubated at 370C in a humidified atmosphere of 
95% air and 5% CO2.
Generation of Catalase and eNOS Adenoviral Expression Constructs 
Adenoviral vectors that express either catalase or eNOS were constructed with the 
pAd/pENTR System (Invitrogen).  Briefly, a pAd/CMV plasmid containing a catalase 
cDNA (cDNA purchased from ATCC, Manassas, VA) or eNOS cDNA (cDNA 
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purchased from ATCC, Manassas, VA) was created and transfected into 293A cells.  A 
selected clone was propagated and viral lysates were collected and titered per the 
manufacturer’s protocol.  The titer for the AdV.catalase preparation was 1.0e1012 plaque-
forming units per mL (pfu/mL) and the titer for the AdV.eNOS preparation was 1.0e1010
pfu/mL.  Transductions of NIH3T3 cells were performed for 120min with virus diluted in 
normal DMEM for a multiplicity of infection (MOI) of 2000.  An MOI=2000 yielded a 
transfection efficiency of 60%.  Verification of transgene expression was performed 
using Western Blot analysis as previously described [13] using 20µg of total protein 
extracts probed with anti-catalase antibody (1:1000, QED, Malden, MA) or anti-eNOS 
antibody (1:1000, BD Biosciences) and normalized to concomitant immunostaining for 
-actin (1:1000, Sigma) on the same blots.  
Protein Extraction 
NIH3T3 cells were grown in 6-well plates to 80% confluence.  They were 
adenovirally transduced with eNOS alone for the control and eNOS + catalase for the 
treatment as stated in the previous section.  Total protein was harvested after 36hrs.
BAECs were grown to confluence and treated for 24hrs with tetrahydro-L-
Biopterin (BH4) (Cayman Chemical, Ann Arbor, MI), L-sepiapterin, or a vehicle control.  
Following treatment, protein was harvested.   
For harvesting, cells were rinsed with DPBS (MediaTech) and RIPA lysis buffer 
added to each well.  Cells were then collected and sheared with a 25-gauge needle 3X.  
Lastly, samples were spun at 14,000Xg for 10min and the supernatant was collected.  
138
Protein concentrations were analyzed using Bio-Rad protein assay (Bio-Rad, Hercules, 
CA) and Bovine Serum Albumin (BSA) for the protein standard curve.
Western blotting 
Western Blot analysis was performed as previously described [14].  Total protein 
extracts (~20µg) were resuspended in 5X Laemmli protein sample buffer and boiled for 
5min.  Total protein was then separated on a 4-20% Tris-SDS-HEPES polyacrylamide 
gel (Gradiopore, Frenchs Forest, Australia) and electrophoretically wet-transferred to a 
Hybond-PVDF membrane (Amersham, Arlington Hts., IL).  The membranes were 
blocked with 5% nonfat dry milk in Tris buffered saline containing 0.1% Tween-20 
(TBST) overnight at 40C.  After blocking, the membranes were incubated at room 
temperature for 2 hrs with the primary antibody (1:1,000 for -eNOS, BD Biosciences 
and 1:1000 -metallothionein-I antibody, QED, Malden, MA), washed 3X with TBST, 
and incubated with a mouse anti-rabbit IgG-horseradish peroxidase conjugated secondary 
antibody (Pierce, Rockford, IL) for 1 hr.  After washing, immunolabeled protein bands 
were visualized using chemiluminescence (SuperSignal West Fempto Substrate Kit, 
Pierce) on a Kodak Image Station 440CF with Kodak 1D Molecular Imaging Software 
and normalized to immunolabeled -actin (1:1000, Sigma) on the same blot.     
Low Temperature Poly Acrylamide Gel Electrophoresis (LT-PAGE) 
 LT-PAGE was used to analyze eNOS dimer levels.  Briefly, NIH3T3 cells were 
transduced for 36hrs with eNOS alone for the control and eNOS + catalase for the 
treatment and BAECs were treated with BH4, L-sepiapterin, or a vehicle control for 
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24hrs.  Next, cells were rinsed 2X with DPBS.  Total protein was harvested and 
concentrations measured as stated in the Western Blot section above.  However, samples 
were not boiled as in a regular Western Blot prior to loading.  Equal protein was loaded 
onto a denaturing polyacrylamide gel and run on ice at 30v for approximately 7hrs.  
Transfer, blocking, and immunoblotting were performed similar to the Western Blot 
method above.      
Catalase Activity Assay 
NIH3T3 cells were grown in 6-well plates to 80% confluence.  They were 
adenovirally transduced with eNOS alone for the control and eNOS + catalase for the 
treatment as stated in the previous section.  Total protein was harvested 36hrs post-
transduction as described in the section above.  Catalase activity was measured 
spectrophotometrically (Shimadzu Biospec) using 40µg of total protein extract from each 
sample.  Briefly, 40µg sample + 99µL 0.05M Potassium Phosphate Buffer (pH=7.0) were 
combined and the spectrophotometer was auto zeroed.  Then, 1µL 3% H2O2 was added to 
the mixture and the absorbance was followed at 240nm for 60sec.  All reagents were used 
at room temperature.         
Hydrogen Peroxide Levels
NIH3T3 cells were grown in 6-well plates to 80% confluence.  They were 
adenovirally transduced with eNOS alone for the control and eNOS + catalase for the 
treatment as stated in the previous section.  After 36hrs, plates were washed with DPBS 
and 1mL fresh media (700µL fresh media + 300µL conditioned media) was added to 
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each well.  Media samples were collected over 4hrs (0, 30, 60, 120, 180, and 240 
minutes) and an equal volume of fresh media was added to the well.  Extracellular H2O2
levels were determined using an Amplex Red H2O2 detection kit (Invitrogen), following 
the manufacturer’s instructions.  A fluorescence plate reader (Fluoroscan) measured 
resorufin fluorescence at an excitation of 560nm and an emission of 590nm and a H2O2
standard curve (0-10µM H2O2) was used to determine its concentration.  Background 
fluorescence was subtracted from all samples and standards.    
Assay for NOS Activity
NOS activity was determined by measuring NOx production in the media with a 
NOx specific probe (Apollo 4000 Free Radical Analyzer, World Precision Instruments, 
Inc.).  NIH3T3 cells were transduced for 24hrs with eNOS or eNOS + catalase and 
treated with BH4 or a vehicle control for an additional 24hrs.  BAECs were treated with 
L-sepiapterin, L-sepiapterin + NAS, or a vehicle control for 24hrs.  NOS activity was 
determined in both NIH3T3 and BAECs following their respective treatments.  Briefly, 
following treatment and a fresh media change, media was collected and either put on ice 
until analysis or frozen for later analysis.  In one set of experiments, BAECs were 
sheared for 15min prior to media collection using a shear plate viscometer at 18v, which 
is comparable to shear forces seen in a blood vessel.  NOx levels were quantified and 
potassium nitrate standards were used to determine NOx levels.
EPR Analysis 
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 NIH3T3 cells were grown in 6-well plates to 80% confluence.  They were 
adenovirally transduced with eNOS alone for the control and eNOS + catalase for the 
treatment.  Twenty four hours post transduction, plates were rinsed with DPBS and 
treated with 100µM BH4 for 24hrs.  The cyclic hydroxylamine, CMH (Alexis 
Biochemicals), spin trap was diluted in EPR Buffer (25µM Dethferioxamine (Sigma-
Aldrich) + 5µM Diethylcarbamate in DPBS without calcium and magnesium) at 
5mg/250µL.  For the last hour of treatment with BH4, 80µL CMH spin trap and 2µL 
DMSO (Sigma) was added to each well.  After 1hr, cells were rinsed with EPR buffer 
and then 1mL EPR buffer was added to each well.  Cells were scraped into a new set of 
tubes and spun at 500 x g for 5min.  Supernatant was removed and 35µL EPR buffer was 
added to each pellet.  Cells were pulled through 25gauge needle to further break open 
cells and put on ice until analysis.  Total protein concentrations were analyzed using Bio-
Rad protein assay (Bio-Rad, Hercules, CA) and Bovine Serum Albumin (BSA) for the 
protein standard curve to normalize the EPR readings.  The cell solution was then loaded 
into a 50µL capillary tube and EPR analysis was done with a MiniScope MS200 ESR 
(Magnettech, Berlin, Germany) at 40mW microwave power, 3,000mG modulation 
amplitude, and 100kHz modulation frequency.  The EPR machine was set to average four 
readings.  EPR spectra were analyzed and measured for amplitude using ANALYSIS 
version 2.02 software (Magnettech).
Measuring BH4 and BH2 Levels 
 BAECs were grown to confluence and treated for 24hrs with L-sepiapterin or 
BH4.  The cells were rinsed with DPBS and then 300µL of extraction buffer was added to 
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each well of the 6-well plates.  The plates were snap frozen and thawed 3X by putting 
plates at -700C for 20min and then back at room temperature for 3min.  Then, the cells 
were scraped and spun in a microfuge tube for 10min at 40C.  The supernatant was put in 
a fresh tube and the pellet was discarded.
 Standards of BH4 were prepared in dH2O and run on the HPLC for standard 
curve.  The HPLC column was washed with 5% methanol for 3min and 200µL of each 
sample was loaded.  Isocratic elution was done for 17min with 5% methanol.  The 
column was cleaned for 8min with 100% methanol and re-equilibrated with 5% methanol 
for 3min before injecting another sample.  The following parameters were used:  Flow 
rate = 0.8mL/min.  Fluorescence detector excitation/emission = 350/450nm, gain = 10, 
and attenuation = 1.  Then, depending on column age, samples were eluted at 12-15min.    
Statistical analysis
Values are expressed as the means ± standard error of the mean from at least three 
experiments.  Statistical analysis between experimental groups was performed by one 
way ANOVA or a T-test using the Graph Pad Prism 4.0 statistical analysis software 
program.  A P < 0.05 was considered statistically significant. 
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RESULTS 
Initially, we verified that the NIH3T3 cells used for these experiments expressed 
low levels of GTP cyclohydrolase, the rate limiting enzyme for the synthesis of 
tetrahydrobiopterin (BH4).  NIH3T3 cells were grown to confluence and protein was 
harvested.  The control for this experiment was ovine lung tissue.  Western blot analysis 
was used to analyze the amount of GTP cyclohydrolase protein.  Results indicated that 
NIH3T3 cells have very low GTP Cyclohydrolase protein levels compared to lung tissue 
(Figure 1).  This data is representative of four independent experiments.   
 Next, we determined the effect of catalase viral transduction on total 
catalase protein levels.  NIH3T3 cells were grown to 80% confluence and transduced 
with endothelial nitric oxide synthase (eNOS) (control) or catalase + eNOS adenovirus at 
MOI=2000.  36hrs post transduction, protein was harvested and Western blot analysis 
was used to determine total catalase protein levels.  Results indicated that catalase viral 
transduction at MOI=2000, gives a 20-fold increase in catalase protein levels compare to 
eNOS viral transduction alone (Figure 2).  This data is representative of four independent 
experiments.   
 Viral transduction gave 20-fold increase in catalase protein, so then we looked at 
catalase activity levels.  Once again, NIH3T3 cells were transduced with eNOS alone or 
eNOS + catalase.  36hrs later, protein was harvested and combined with a set amount of 
hydrogen peroxide (H2O2) to measure catalase’s ability to dismutate the H2O2.  Results 
found that a 20-fold increase in protein corresponded to a 6-fold increase in catalase 
activity (Figure 3).  This data is representative of four independent experiments.      
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Following that, we determined whether the increases in catalase protein and 
activity would affect basal H2O2 levels in NIH3T3 cells.  Once again, NIH3T3 cells were 
transduced with eNOS alone or eNOS + catalase.  36hrs later, cells were rinsed and fresh 
media was added.  Media samples were collected over the next 4hrs and H2O2levels were 
measured using the commercially available Amplex Red kit.  There was nearly 30% less 
H2O2in eNOS + catalase vs eNOS viral transduction alone (Figure 4).  This data is 
representative of four independent experiments.      
Knowing that the eNOS cofactor, BH4, has very low expression in NIH3T3 cells, 
we decided to see what effect catalase transduction would have on total eNOS protein.  
NIH3T3 cells were virally transduced with eNOS alone or eNOS + catalase.  Protein was 
harvested and western blot analysis was used to determine total eNOS protein levels.  
Results found nearly a 50% increase in total eNOS protein compared to eNOS 
transduction alone (Figure 5).  This data suggests that a major role of BH4 may be to act 
as an antioxidant to help maintain eNOS protein levels.  This data is representative of 
four independent experiments.          
 eNOS is only active as a homodimer, therefore we looked at the effect of catalase 
transduction in NIH3T3 cells on eNOS monomer and dimer levels.  Protein from the 
previous experiment was utilized for these studies.  Protein was subjected to low 
temperature polyacrylamide gel electrophoresis to separate monomer and dimer eNOS 
proteins.  Results are represented at a dimer to monomer ratio, so a higher ratio represents 
more of the active form of eNOS.  There was nearly a 2-fold dimer to monomer ratio 
increase with catalase transduction (Figure 6).  This further supports BH4’s antioxidant 
role, not only in total eNOS protein maintenance, as seen in the previous experiment, but 
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also in maintaining the active dimeric form of eNOS.  This data is representative of four 
independent experiments.            
The next step was to look at the effect of catalase transduction on eNOS activity.  
NIH3T3 cells were grown to 80% confluence and virally transduced with eNOS or eNOS 
+ catalase adenovirus.  24hrs later cells were treated for 24hrs with BH4 or a vehicle 
control.  Following this treatment, media from virally transduced NIH3T3 cells was 
collected and NOx levels were analyzed using a NOx-specific probe.  A standard curve of 
various concentrations of potassium nitrate was used to determine the NOx levels in the 
media.  Results indicated that without BH4 treatment, there was a nearly a 30% increase 
in eNOS activity with catalase transduction (Figure 7).  However, with BH4 treatment, 
there was no difference with catalase transduction (Figure 7).  This data is representative 
of four independent experiments.            
A series of experiments to look further at the role of BH4 were done in bovine 
aortic endothelial cells (BAECs).  BAECs have very high levels of BH4 compared to the 
NIH3T3 cells.  We hope that the direct addition of BH4 or L-sepiapterin, which serves as 
a substrate for BH4 synthesis through the pterin salvage pathway, independent of GTP 
cyclohydrolase, will give similar results compared to the catalase transduction.
In the first experiment, BAECs were grown to confluence and treated for 24hrs 
with various doses of BH4 and L-sepiapterin.  Media was collected and reactive oxygen 
species (ROS), specifically H2O2, were measured using the Amplex Red kit.  Results 
demonstrate a dose dependent decrease in ROS levels with L-sepiapterin treatment.  At 
100µM BH4, there is a significant decrease in ROS, but at 500µM, ROS is significantly 
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higher (Figure 8).  At such a high level, this increase may be due to toxicity.  This data is 
representative of four independent experiments.            
Next, we looked at BH4 and BH2 levels in BAECs following L-sepiapterin or BH4
treatment.  BAECs were grown to confluence and treated with L-sepiapterin, BH4, or a 
vehicle control for 24hrs.  Protein was harvested and HPLC was used to measure BH4
and BH2 levels.  Both L-sepiapterin and BH4 treatment increased BH4 and BH2 levels, but 
to a greater extent with L-sepiapterin (Figure 9).  This data is representative of four 
independent experiments.   
Using the same spectrophotometric assay used to measure catalase activity, we 
next tested the direct addition of BH4 on the dismutation rate of H2O2.  We found about a 
15-fold increase in H2O2 dismutation with BH4 compared to a vehicle control (Figure 10).  
These results strongly support BH4’s role as an antioxidant.  This data is representative of 
four independent experiments.      
BH4 does have very strong antioxidant properties.  Next, we looked at its effect on 
eNOS dimer levels.  BAECs were grown to confluence and then treated with BH4, L-
sepiapterin, or a vehicle control for 24hrs.  Similar to results in NIH3T3 cells following 
catalase transduction, BH4 and L-sepiapterin increased eNOS dimer levels 10-15% 
(Figure 11).  This data is representative of four independent experiments. 
Lastly, we looked at the effect of BH4 and L-sepiapterin on eNOS activity in 
BAECs.  BAECs were grown to confluence and treated for 24hrs with L-sepiapterin, L-
sepiapterin + N-acetyl-serotonin (NAS), or a vehicle control.  L-sepiapterin caused a 30% 
increase in NOx release (Figure 12), but this increase was abolished with the specific 
inhibitor of L-sepiapterin, NAS (Figure 12).  The direct addition of BH4 to BAECs did 
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not significantly increase eNOS activity (Figure 13).  This may be because BH4 levels 
and/or eNOS activity may already be maximal in these cells.  However, exposing the 
cells to 20min of shear alone increased eNOS activity nearly 3-fold and with the addition 
of BH4, increased it nearly 7-fold (Figure 13).  This data is representative of four 
independent experiments.     
 Going back to the NIH3T3 cells, we decided to look at ROS production following 
catalase overexpression and BH4 treatment.  NIH3T3 cells were grown to 80% 
confluence and virally transduced with eNOS or eNOS + catalase.  24hrs later, cells were 
treated with BH4 or a vehicle control for 24hrs.  At 23hrs, the superoxide specific spin 
trap, CMH, was added to each well.  Following treatment, cells were harvested in EPR 
buffer.  EPR analysis indicated that catalase transduction significantly decreased ROS 
levels with or without BH4 treatment (Figure 14). BH4 treatment further decreased ROS 
levels in both eNOS and eNOS + catalase transduced samples.  This data is representative 
of four independent experiments.     
    
148
DISCUSSION 
Endothelial nitric oxide synthase (eNOS) become uncoupled in persistent 
pulmonary hypertension of the newborn (PPHN), such that there is decreased production 
of the vasodilator, nitric oxide (NO) and increased production of cellular oxidants, such 
as hydrogen peroxide (H2O2) and superoxide (O2.-).  NOS enzymes do have the ability to 
secrete O2.-  [15-17].  The four redox active prosthetic groups (FAD, FMN, heme, and 
BH4) could potentially pass electrons to molecular oxygen (O2).  To prevent this 
uncoupling from NO synthesis, electron transfers in NOS enzymes are tightly regulated.  
A functional eNOS transfers electrons from NADPH through the flavins, FAD and FMN, 
in the carboxy-terminal reductase domain to the heme in the amino-terminal oxygenase 
domain.  The reaction oxidizes L-arginine to L-citrulline and NO.   If this electron flow is 
disturbed, superoxide is generated from the oxygenase domain instead of NO by 
dissociation of the ferrous dioxygen complex [18].  The production of nitric oxide (NO) 
in the vessel wall by the eNOS is dependent on essential enzyme cofactors, including the 
most potent naturally occurring reducing agent, tetrahydrobiopterin (BH4).  BH4 is 
thought to maintain the eNOS homodimer, but we wanted to determine whether this was 
dimer maintenance was due to its high antioxidant capability. 
This study utilized NIH3T3 cells, which express very low levels of GTP 
cyclohydrolase, which is the rate limiting enzyme for the synthesis of BH4, and do not 
express eNOS.  These cells have high transduction efficiency and will lift shortly after 
reaching confluence; therefore all transductions were done at ~80% confluence and 
treatments/analysis done at confluence prior to cell lifting.  After 36hrs, eNOS protein 
expressed very nicely compared to a transfection control, which contained no eNOS 
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(Data not shown).  Catalase transduction resulted in a 20-fold increase in catalase protein 
(Figure 3) and was associated with a 6-fold increase in catalase activity (Figure 4).
Decreasing the basal oxidative environment in NIH3T3 cells by virally transducing with 
catalase (Figure 4) significantly increased total eNOS protein.  These results suggest that 
without the antioxidant cofactor BH4, eNOS may be vulnerable to even basal levels of 
cellular oxidants and support BH4’s role as an antioxidant.
eNOS plays an important role in regulating vascular smooth muscle tone and 
blood pressure through its generation of NO, which also protects the intima of the vessels 
from platelet aggregation and leukocyte adhesion, and prevents proliferation of vascular 
smooth muscle [19, 20].  This enzyme is only active, however, as a homodimeric enzyme 
[21-23].  In the absence of adequate levels of BH4, eNOS becomes uncoupled from the 
L-arginine oxidation and molecular oxygen is reduced to form superoxide [24].  eNOS 
uncoupling modulates endothelial dysfunction in various vascular disorders, including 
atherosclerosis [25], diabetes [26, 27], hypertension [28], and hypercholesterolemia [29].  
It is now well established that BH4 is important for the coupling of eNOS  [30, 31].  The 
increased superoxide produced by an uncoupled eNOS reduces NO production and 
increased production of peroxynitrite, a production of superoxide reacting with available 
NO.  Since BH4 is thought to maintain the eNOS dimer, we tested whether decreasing the 
oxidative environment in NIH3T3 cells would increase eNOS dimer and did find a 2-fold 
increase in eNOS dimer/monomer ratio (Figure 6).  With low BH4 levels in NIH3T3 
cells, these results suggest that BH4’s antioxidant properties are important in eNOS dimer 
maintenance. 
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When in an active dimeric state and tightly coupled with sufficient cofactor 
levels, eNOS produces NO.  In looking at the effect of catalase transduction on eNOS 
activity in the presence of low levels of BH4, we found a 30% increase in NOx release 
(Figure 7).  The addition of BH4 to these cells restored eNOS activity in the eNOS 
transduced only sample to the level of the eNOS/catalase dually transduced sample 
(Figure 7).  This further supports our hypothesis that BH4’s antioxidant properties are 
important for eNOS activity. 
For the next series of experiments, we utilized a system with normal basal BH4
levels, BAECs.  The direct addition of BH4 or L-sepiapterin, a substrate for BH4 
synthesis through the pterin salvage pathway, independent of GTP cyclohydrolase, gave 
us more insight into BH4’s role in the regulation of eNOS and a comparison for the 
NIH3T3 eNOS/catalase dually transduced samples. 
  As expected, both BH4 and L-sepiapterin significantly decreased ROS levels in 
BAECs (Figure 8), specifically H2O2, as measured by Amplex Red assay.  However, at 
500µM BH4, ROS levels significantly increased (Figure 8).  Too much antioxidant in the 
cell is most likely toxic.  The addition of BH4 to BAECs significantly increased cellular 
BH2 levels, the oxidized inactive form of tetrahydrobiopterin, three-fold and BH4 levels
nearly six-fold (Figure 9).  However, L-sepiapterin addition significantly increased 
cellular BH2 levels about 20-fold and BH4 levels nearly 150-fold (Figure 9).
Next, we measured the dismutation rate of H2O2 by BH4 in BAECs and found 
about a 7-fold increase (Figure 10).  These results were no surprise since it is known that 
BH4 is the most potent naturally occurring reducing agent, but they do give a quantitative 
measurement of its reducing power.      
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 BH4 and L-sepiapterin had a similar effect on BAECs as did eNOS/catalase 
transduction in NIH3T3 cells, significantly increasing eNOS dimer levels 10-15% 
compared to a vehicle control.  This does demonstrate that BH4 is important in 
maintaining eNOS dimer levels, possible due to its antioxidant properties.
Even though L-sepiapterin increased BH4 levels 150-fold (Figure 9), it only 
significantly increased eNOS activity about 30% compared to vehicle control BAECs 
(Figure 12).  It also increased BH2 levels 20-fold (Figure 9).  Increased BH2 can displace 
pre-bound BH4 from its eNOS binding site in the oxygenase domain [32], which could 
enhance eNOS uncoupling, thus lowering eNOS activity and explaining this result.
The addition of BH4 to BAECs interestingly did not result in a significant increase 
in eNOS activity (Figure 13).  This may be due to the fact that it only increased 
intracellular BH4 levels about six-fold and/or because BAEC eNOS is already quite active 
basally.  Fluid shear stress is defined as the tractive force produced by moving a viscous 
fluid (blood) on a solid body (vessel wall), constraining its motion [33].  It is known to 
initiate diverse responses in endothelial cells, including increases in NOS activity, NO 
production, and eNOS mRNA/protein levels [34-41].  Our results indicated that shear 
significantly increased eNOS activity in BAECs and even further increased it with the 
addition of BH4 (Figure 13). 
Our last experiments went back to the NIH3T3 cells and looked at ROS 
production by EPR analysis in cells transduced with eNOS or eNOS/catalase and treated 
with BH4 or a vehicle control.  eNOS/catalase transduction significantly decreased ROS 
production three-fold compared to eNOS transduction alone (Figure 14).  However, the 
addition of BH4 to the eNOS transduced sample brought ROS levels back to that of 
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eNOS/catalase transduced (Figure 14).  As expected, the eNOS/catalase transduced and 
treated with BH4 resulted in the lowest ROS levels (Figure 14).
In conclusion, our results indicate that BH4’s high antioxidant potential plays a 
major role in its regulation of eNOS protein levels and activity.  NIH3T3 cells have very 
low BH4 levels, which may not increase the overall oxidative environment, since cellular 
antioxidants tend to compensate for a lack of another antioxidant, but there would be less 
BH4 available to associate with the transfected eNOS.  Thus, eNOS may be more 
vulnerable as protected from the various oxidants present in the cell, leading to decreased 
protein and activity.  By decreasing the oxidative environment with catalase transduction, 
we significantly increased eNOS total protein, dimer/monomer protein ratio, and activity.
The direct addition of BH4 to NIH3T3 cells significantly decreased ROS levels.  Studies 
in BAECs, which contain much higher levels of BH4 protein, further confirmed the 
previous results by demonstrating that the addition of BH4 or L-sepiapterin significantly 
decreased the oxidative environment and increased eNOS dimer protein and activity 
levels.  Further studies need to be done, especially on purified protein, to look further into 
BH4’s antioxidant role in eNOS regulation.  These studies do provide valuable insights 
into BH4’s role in eNOS regulation and may help in the development of treatments for 
vascular diseases, such as PPHN, which are characterized by endothelial dysfunction.
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FIGURE LEGENDS 
Fig. 1.  NIH3T3 cells have very little GTP Cyclohydrolase protein levels compared to 
lung tissue.  Protein was harvested from NIH3T3 cells and lung tissue.  Western blot 
analysis was used to analyze GTP Cyclohydrolase protein levels.  All values are mean ± 
SEM (n=4). * P<0.05 vs. Lung Tissue. 
Fig. 2.  Catalase protein levels in NIH3T3 cells after transduction with catalase 
adenovirus increases expression 20-fold.  NIH3T3 cells were co-transduced with catalase 
and eNOS adenoviruses at MOI=1000.  36hrs later, cell protein was harvested.  Western 
blot analysis was used to analyze human catalase levels.  All values are mean ± SEM 
(n=4). * P<0.05 vs. eNOS. 
Fig. 3.  Catalase activity increases 6-fold in catalase transduced NIH3T3 cells.  NIH3T3 
cells were co-transduced with catalase and eNOS adenoviruses at MOI=1000.  36hrs 
later, catalase activity was measured using spectrophotometric assay.  All values are 
mean ± SEM (n=4). * P<0.05 vs. eNOS. 
Fig. 4.  Hydrogen peroxide levels decrease nearly 30% in catalase transduced NIH3T3 
cells.  NIH3T3 cells were co-transduced with catalase and eNOS adenoviruses at 
MOI=1000.  36hrs later, H2O2 levels were measured using DCF-DA and reading on a 
multiscan at 360nm.  All values are mean ± SEM (n=4). * P<0.05 vs. eNOS. 
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Fig. 5.  eNOS protein levels in NIH3T3 cells after transduction with eNOS and catalase 
adenovirus increases expression nearly 50%.  NIH3T3 cells were co-transduced with 
catalase and eNOS adenoviruses at MOI=1000.  36hrs later, cell protein was harvested.  
Western blot analysis was used to analyze eNOS protein levels.  All values are mean ± 
SEM (n=4). * P<0.05 vs. eNOS. 
Fig. 6.  Catalase transduction leads to a dimer shift in NIH3T3 cells. NIH3T3 cells were 
co-transduced with catalase and eNOS adenoviruses at MOI=1000.  36hrs later, cell 
protein was harvested.  LT-PAGE and Western blot analysis was used to analyze eNOS 
dimer/monomer protein levels.  All values are mean ± SEM (n=4). * P<0.05 vs. eNOS. 
Fig. 7.  Catalase transduction leads to an increase in eNOS activity.  NIHT3 cells were 
co-transduced with catalase and eNOS adenoviruses at MOI=1000.  24hrs later, cells 
were treated for 24hrs with 100mM BH4.  Media was collected and NOx levels were 
measured using an NOx specific probe.  All values are mean ± SEM (n=4). * P<0.05 vs. 
eNOS. 
Fig. 8. Treating BAECs with either BH4 or L-Sepiapterin leads to decreases in ROS 
levels in cells.  BAECs were grown to confluence and treated with BH4 or L-Sepiapterin.  
Media was collected and Amplex Red assay was performed.  All values are mean ± SEM 
(n=4). * P<0.05 vs. 0.
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Fig. 9. Both L-Sepiapterin and BH4 cause increases in BH4 and BH2 levels in BAECs.  
BAECs were grown to confluence and treated with L-Sepiapterin or BH4.  Cellular 
protein was harvested and HPLC was used to analyze BH2 (A) and BH4  (B) levels.  All 
values are mean ± SEM (n=4). * P<0.05 vs. Untreated.
Fig. 10. BH4 causes the rate of H2O2 dismutation to increase nearly 15-fold from 
baseline.  Solutions of hydrogen peroxide were analyzed for dimutation rates with or 
without BH4.  All values are mean ± SEM (n=4). * P<0.05 vs. Untreated.
Fig. 11. Both BH4 and L-Sepiapterin cause increases in eNOS dimer levels.  BAECs 
were grown to confluence and treated with BH4 or L-Sepiapterin.  Cellular protein was 
harvested and eNOS dimer levels were measured using LT-PAGE.  All values are mean 
± SEM (n=4). * P<0.05 vs. Untreated.
Fig. 12. L-Sepiapterin causes increases in eNOS activity in BAECs.  BAECs were grown 
to confluence and treated with L-Sepiapterin +/- N-acetyl-serotonin (blocks conversion of 
L-sepiapterin to BH4).  All values are mean ± SEM (n=4). * P<0.05 vs. Untreated.
Fig. 13.  BH4 and Shear in combination cause increases in eNOS activity over shear 
alone.  BAECs were grown to confluence and treated or not with BH4.  Cells were then 
exposed with shear forces with a shear plate viscometer for 20 minutes.  Media was 
collected and analyzed for NOx levels using an NO specific probe.  All values are mean 
± SEM (n=4). * P<0.05 vs. Untreated.
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Fig. 14.  BH4 causes decreases in ROS levels in virally transduced NIH3T3 cells.  
NIH3T3 cells were grown to 80% confluence and virally transduced with eNOS or 
eNOS+Catalase.  After 36hrs, cells were harvested and EPR was run using the CMH spin 
trap.  All values are mean ± SEM (n=6). * P<0.05 vs. eNOS. 
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COMMON CONCLUSIONS 
These studies furthered the understanding of the regulation of endothelial nitric 
oxide synthase (eNOS) at the transcriptional and post-translational levels.   The 
development of persistent pulmonary hypertension of the newborn (PPHN), a very 
serious disease affecting nearly 5 in 1000 newborns each year [5] and is associated with a 
decrease in the activity and expression of eNOS.  Our hypothesis was proven correct such 
that eNOS is regulated by nitric oxide (NO) and reactive oxygen species (ROS), 
specifically hydrogen peroxide (H2O2) through an increase in intracellular zinc (Zn), thus 
activating the heavy metal responsive transcription factor 1 (MTF-1), which binds to the 
5’ flanking region of the eNOS promoter.  These novel studies and future work may help 
to identify new targets and novel therapies for PPHN.  
Chapter 1 
 Some early developmental endothelial cell studies in our lab indicated that 
increases in eNOS expression and activity correlated with increases in cellular levels of 
labile zinc (Zn) (Figures 3 & 4).  We also analyzed the eNOS promoter and found the 
presence of a heavy metal response element (HRE) located at -899/-893 in the 5’-
flanking sequence of the human eNOS gene.  Therefore, in our first study, we set out to 
define the mechanism by which zinc mediated eNOS expression at the transcriptional 
level and eNOS activity at the post-translational level.  We hypothesized that the addition 
of zinc to fetal pulmonary aortic endothelial cells (FPAECs) would activate heavy metal 
responsive transcription factor 1 (MTF-1) causing nuclear translocation and binding to 
the HRE in the 5’-flanking region of the eNOS gene.  This in turn would lead to 
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increased in eNOS protein expression.  Since zinc holds the eNOS homo-dimer together, 
we also hypothesized that the addition of zinc would induce increased in eNOS activity 
as measured by a release of NO.   
Our hypothesis was proven correct in that the addition of low micro-molar levels 
of zinc to FPAECs increased eNOS dimer protein, total protein, and eNOS promoter-
luciferase activity.  It also significantly increased MTF-1 nuclear translocation and 
binding to the eNOS MRE.  Zinc depletion studies yielded results contrary to our 
expectations, however, they did not affect eNOS dimer levels, indicating that once the 
eNOS dimer is formed it remains 
tightly bound.
Chapter 2
 PPHN is associated with 
endothelial dysfunction, and endothelial 
cells have been shown to increase their 
generation of hydrogen peroxide and 
superoxide both from the “uncoupling” 
of endothelial nitric oxide synthase 
(eNOS) and from the activation of 
nicotinamide adenine dinucleotide 
phosphate-oxidase (NADPH) complex.  
Both eNOS mRNA and protein levels 
Fig.  6.  eNOS dimer levels dose 
dependently increase with ZnCl2 treatment 
up to 100µM and then decrease at 200µM.
BAECs were treated with ZnCl2 for 4hrs.
Protein was harvested and LT-PAGE was 
used to separate eNOS dimer and blots 
were probed with eNOS Ab.  All values are 
mean ± SEM (n=4). * P<0.05 vs. 0µM 
ZnCl2.
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are decreased in PPHN, contributing to decreased levels of NO production.   Under 
normal in vivo conditions, endothelial cells are continually exposed to low amounts of 
nitric oxide (NO) and H2O2.  Previous in vitro data from our lab indicated that high levels 
of NO and H2O2 can actually break up the eNOS dimer [99-101].  However, our 
preliminary studies for this chapter indicated that low levels of these oxidants increased 
eNOS expression.  Also, both NO and H2O2 are known to s-nitrosylate metallothionein 
(MT-1), thus increasing cellular free zinc [72-74].  Therefore, our second study 
investigated whether the addition of NO and H2O2 increased eNOS expression and 
activity by increasing cellular free zinc levels.  We hypothesized that low micro-molar 
levels of NO and H2O2 increase eNOS 
expression and activity by increasing 
cellular free zinc. 
 Our hypothesis was proven correct 
such that both NO and H2O2 increased 
cellular levels of labile zinc.  It also 
increased eNOS mRNA, total protein, and 
promoter-luciferase activity.  Both NO and 
H2O2 caused significantly higher zinc 
dependent nuclear translocation and binding 
of the eNOS promoter by MTF-1.  Findings 
from this study demonstrate a pathway of 
eNOS activation by low dose NO and H2O2
Fig. 7.  4hr Zinc treatments of 50uM and 
greater lead to increased ROS production 
in BAECs.  BAECs were treated for 4hrs 
with ZnCl2.  At 3.5hrs, CMH spin trap 
was added to the cells.  EPR analysis was 
performed on the samples. All values are 
mean ± SEM (n=4). * P<0.05 vs. 0µM 
ZnCl2.
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through free zinc release and heavy metal responsive transcription factor 1 (MTF-1) 
activation.
Chapter 3 
 Hypertensive vasoconstriction is postulated to involve the degradation of NO by 
reactive oxygen species (ROS), especially the superoxide anion.  Antioxidant therapy has 
been proposed as a treatment regimen for pulmonary hypertension and other pathologies 
linked to endothelial dysfunction.  Results from the first two chapters indicated that low 
levels of zinc, NO, or H2O2 can actually stimulate eNOS, however, when at higher levels, 
this stimulation was abolished.  Using electron paramagnetic resonance (EPR), we looked 
at ROS production in endothelial cells following exposure to increasing, non-toxic doses 
of zinc (Figure 7).  ROS levels were much lower in exposures that stimulated eNOS 
compared to the ROS levels in exposures to higher levels of zinc that did not stimulate 
eNOS (Figure 6 & 7). Since the critical mediator of pulmonary vasorelaxation is 
generation of NO by eNOS, we wanted to determine the effect of ROS, specifically 
superoxide (O2
.-) on eNOS function in ovine pulmonary arterial endothelial cells 
(PAECs).
 Therefore, we set out to establish whether modulating the cellular redox state in 
endothelial cells would alter eNOS expression and/or activity.  We hypothesized that 
high levels of O2
.- would indirectly inhibit eNOS by scavenging NO since NO readily 
reacts with O2
.- to produce peroxynitrite.  Results indicate that our hypothesis was proven 
at least partially incorrect.  At high levels, O2
.- decreased eNOS protein levels and the 
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catalytic capability of the enzyme.  Some O2
.- may be directly inactivating NO, however, 
at the levels used in these experiments, O2
.- actually caused eNOS fragmentation.   
These experiments suggest that NO-NOS system represents a complex 
bioregulated pathway whose regulation is tightly associated with the redox status of the 
cell.  Thus, the increases in ROS that may be involved in the development of endothelial 
dysfunction, which is associated with a number of vascular diseases, may cause a 
reduction in eNOS activity, possibly by inducing eNOS fragmentation and directly 
interacting with NO to form more reactive radicals.                  
Chapter 4 
Persistent pulmonary hypertension of the newborn (PPHN) is associated with 
increased ROS production.  Oxidant production plays an important role both in the 
normal functioning of the vascular system as well as the pathogenesis of vascular disease.
As we saw in chapters 2 & 3, eNOS is dynamically regulated by the redox status of the 
cell.  The production of nitric oxide (NO) in the vessel wall by the eNOS is dependent on 
essential enzyme cofactors, including the most potent naturally occurring reducing agent, 
tetrahydrobiopterin (BH4).  In a study by Wang, et al., rats were supplemented with 
fructose in their diet, which is known to produce oxidative stress in vivo, and it was 
found that endothelium-dependent relaxations were impaired [102].  Supplementing the 
fructose-fed rats with BH4 in the water partially restored endothelium-dependent vascular 
relaxations and eNOS protein levels within the rat aortas [102]. Although BH4 is thought 
to maintain eNOS dimer, the exact mechanism of this maintenance is unknown. 
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To look further into the regulation of eNOS by ROS, we explored the role of BH4.
Utilizing NIH3T3 cells, a line with very low BH4 levels, and bovine aortic endothelial 
cells (BAECs), we hypothesized that BH4’s role in the regulation of eNOS was due to its 
high antioxidant potential.  Our results in NIH3T3 cells, which have very low levels of 
BH4, demonstrate that catalase transduction decreased ROS levels, specifically H2O2, and 
increased eNOS total protein, dimer/monomer protein ratio, and eNOS activity.  In 
BAECs, the addition of BH4 or L-sepiapterin, the substrate for the synthesis of BH4,
decreased ROS levels and increased eNOS dimer levels and activity.  The addition of 
BH4 to NIH3T3 cells also decreased ROS production.  The results supported the 
hypothesis such that the association of BH4 with eNOS regulates eNOS protein levels and 
activity mainly due to its high antioxidant potential.  
Summary/Future Studies 
In summary, these studies establish a link in endothelial cells between the 
oxidative environment, cellular zinc homeostasis and eNOS protein and activity.  
Maintaining certain dietary levels of zinc could be important in retaining healthy 
endothelial function and zinc supplementation during pregnancy may help minimize 
symptoms PPHN by increasing eNOS levels and activity prior to birth.   
The regulation of the NO-NOS system is complex and does involve many factors.  
It would be interesting to look further into the involvement of other zinc-finger 
transcription factors, such as SP-1 and AP-1, in the regulation of eNOS.  Other eNOS 
cofactors and associated proteins, such as HSP90 may also play important roles in eNOS 
regulation.  Certain hormones, such as estrogen, play an important role in the fetal-to-
181
newborn transition and it would be interesting to explore their role in the cellular 
oxidative environment, zinc homeostasis, and eNOS regulation.  Continuing to further the 
understanding of eNOS regulation may help to identify new pathways and novel 
therapies for cardiovascular diseases such as PPHN. 
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